| Year |
Citation |
Score |
| 2024 |
Cattaneo G, Ventin M, Arya S, Kontos F, Michelakos T, Sekigami Y, Cai L, Villani V, Sabbatino F, Chen F, Sadagopan A, Deshpande V, Moore PA, Ting DT, Bardeesy N, ... ... Ferrone S, et al. Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. Cancer Letters. 587: 216713. PMID 38364961 DOI: 10.1016/j.canlet.2024.216713 |
0.303 |
|
| 2023 |
Nounamo B, Jousheghany F, Siegel ER, Post SR, Kelly T, Ferrone S, Kieber-Emmons T, Monzavi-Karbassi B. VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen. International Journal of Molecular Sciences. 24. PMID 36768830 DOI: 10.3390/ijms24032506 |
0.345 |
|
| 2022 |
Nota SPFT, Osei-Hwedieh DO, Drum DL, Wang X, Sabbatino F, Ferrone S, Schwab JH. Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy. Frontiers in Oncology. 12: 939166. PMID 36110930 DOI: 10.3389/fonc.2022.939166 |
0.372 |
|
| 2022 |
Ladányi A, Hegyi B, Balatoni T, Liszkay G, Rohregger R, Waldnig C, Dudás J, Ferrone S. HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab. Pathology Oncology Research : Por. 28: 1610297. PMID 35531074 DOI: 10.3389/pore.2022.1610297 |
0.358 |
|
| 2022 |
Michelakos T, Kontos F, Kurokawa T, Cai L, Sadagopan A, Krijgsman D, Weichert W, Durrant LG, Kuppen PJK, R Ferrone C, Ferrone S. Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer. Journal For Immunotherapy of Cancer. 10. PMID 35277460 DOI: 10.1136/jitc-2021-004115 |
0.331 |
|
| 2021 |
Sadagopan A, Michelakos T, Boyiadzis G, Ferrone C, Ferrone S. Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review. Jama Oncology. PMID 34940799 DOI: 10.1001/jamaoncol.2021.5970 |
0.357 |
|
| 2021 |
Maggs L, Sadagopan A, Moghaddam AS, Ferrone S. HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy. Trends in Cancer. PMID 34489208 DOI: 10.1016/j.trecan.2021.07.006 |
0.4 |
|
| 2021 |
Maggs L, Cattaneo G, Dal AE, Moghaddam AS, Ferrone S. CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma. Frontiers in Neuroscience. 15: 662064. PMID 34113233 DOI: 10.3389/fnins.2021.662064 |
0.305 |
|
| 2021 |
Lichtman EI, Du H, Shou P, Song F, Suzuki K, Ahn S, Li G, Ferrone S, Su L, Savoldo B, Dotti G. Preclinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T cells for the Treatment of Acute Myeloid Leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33531429 DOI: 10.1182/Blood-2018-99-113468 |
0.39 |
|
| 2020 |
Patel SS, Nota SP, Sabbatino F, Nielsen GP, Deshpande V, Wang X, Ferrone S, Schwab JH. Defective HLA Class I Expression and Patterns of Lymphocyte Infiltration in Chordoma Tumors. Clinical Orthopaedics and Related Research. PMID 33273248 DOI: 10.1097/CORR.0000000000001587 |
0.381 |
|
| 2020 |
Jongsma MLM, de Waard AA, Raaben M, Zhang T, Cabukusta B, Platzer R, Blomen VA, Xagara A, Verkerk T, Bliss S, Kong X, Gerke C, Janssen L, Stickel E, Holst S, ... ... Ferrone S, et al. The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses. Immunity. PMID 33271119 DOI: 10.1016/j.immuni.2020.11.003 |
0.39 |
|
| 2020 |
Kontos F, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, Ferrone S. B7-H3: an attractive target for antibody-based immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33051306 DOI: 10.1158/1078-0432.CCR-20-2584 |
0.319 |
|
| 2020 |
Song L, Bretz AC, Gravemeyer J, Spassova I, Muminova S, Gambichler T, Sriram A, Ferrone S, Becker JC. The HDAC Inhibitor Domatinostat Promotes Cell Cycle Arrest, Induces Apoptosis and Increases Immunogenicity of Merkel Cell Carcinoma Cells. The Journal of Investigative Dermatology. PMID 33002502 DOI: 10.1016/j.jid.2020.08.023 |
0.361 |
|
| 2020 |
Vallera DA, Ferrone S, Kodal B, Hinderlie P, Bendzick L, Ettestad B, Hallstrom C, Zorko NA, Rao A, Fujioka N, Ryan CJ, Geller MA, Miller JS, Felices M. NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. Cancers. 12. PMID 32961861 DOI: 10.3390/Cancers12092659 |
0.443 |
|
| 2020 |
Leuci V, Donini C, Grignani G, Rotolo R, Mesiano G, Fiorino E, Gammaitoni L, D'Ambrosio L, Merlini A, Landoni E, Medico E, Capellero S, Giraudo L, Cattaneo G, Iaia I, ... ... Ferrone S, et al. CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32900797 DOI: 10.1158/1078-0432.Ccr-20-0357 |
0.327 |
|
| 2020 |
Ascierto PA, Puzanov I, Agarwala SS, Blank C, Carvajal RD, Demaria S, Dummer R, Ernstoff M, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Lo RS, Long GV, et al. Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). Journal of Translational Medicine. 18: 346. PMID 32894202 DOI: 10.1186/S12967-020-02482-X |
0.374 |
|
| 2020 |
Chauvin JM, Ka M, Pagliano O, Menna C, Ding Q, DeBlasio R, Sander C, Hou J, Li XY, Ferrone S, Davar D, Kirkwood JM, Johnston RJ, Korman AJ, Smyth MJ, et al. IL-15 stimulation with TIGIT blockade reverses CD155-mediated NK cell dysfunction in melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32591463 DOI: 10.1158/1078-0432.Ccr-20-0575 |
0.341 |
|
| 2020 |
Maggs L, Ferrone S. Improving the clinical significance of preclinical immunotherapy studies through incorporating tumor microenvironment-like conditions. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32571789 DOI: 10.1158/1078-0432.Ccr-20-0358 |
0.338 |
|
| 2020 |
Ladányi A, Papp E, Mohos A, Balatoni T, Liszkay G, Oláh J, Varga A, Lengyel Z, Emri G, Ferrone S. Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in patients with melanoma. Journal For Immunotherapy of Cancer. 8. PMID 32554608 DOI: 10.1136/Jitc-2019-000209 |
0.43 |
|
| 2020 |
Michelakos T, Cai L, Villani V, Sabbatino F, Kontos F, Fernández-Del Castillo C, Yamada T, Neyaz A, Taylor MS, Deshpande V, Kurokawa T, Ting DT, Qadan M, Weekes CD, Allen JN, ... ... Ferrone S, et al. Tumor microenvironment immune response in pancreatic ductal adenocarcinoma patients treated with neoadjuvant therapy. Journal of the National Cancer Institute. PMID 32497200 DOI: 10.1093/Jnci/Djaa073 |
0.309 |
|
| 2020 |
Such L, Zhao F, Liu D, Thier B, Le-Trilling VTK, Sucker A, Coch C, Pieper N, Howe S, Bhat H, Kalkavan H, Ritter C, Brinkhaus R, Ugurel S, Köster J, ... ... Ferrone S, et al. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. The Journal of Clinical Investigation. PMID 32427578 DOI: 10.1172/Jci131572 |
0.474 |
|
| 2020 |
Sun T, Yang W, Toprani SM, Guo W, He L, DeLeo AB, Ferrone S, Zhang G, Wang E, Lin Z, Hu P, Wang X. Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram. Cell Communication and Signaling : Ccs. 18: 36. PMID 32138738 DOI: 10.1186/S12964-019-0507-3 |
0.379 |
|
| 2020 |
Sharma P, Diergaarde B, Ferrone S, Kirkwood JM, Whiteside TL. Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. Scientific Reports. 10: 92. PMID 31919420 DOI: 10.1038/S41598-019-56542-4 |
0.387 |
|
| 2020 |
Seliger B, Ferrone S. HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease. Methods in Molecular Biology (Clifton, N.J.). 2055: 325-350. PMID 31502159 DOI: 10.1007/978-1-4939-9773-2_15 |
0.499 |
|
| 2020 |
Marleau AM, Jacobs MT, Gruber N, Rodell TC, Ferrone S, Whiteside TL. Abstract 4509: Targeting tumor-derived exosomes using a lectin affinity hemofiltration device Immunology. 80: 4509-4509. DOI: 10.1158/1538-7445.Am2020-4509 |
0.335 |
|
| 2019 |
Krokhotin A, Du H, Hirabayashi K, Popov K, Kurokawa T, Wan X, Ferrone S, Dotti G, Dokholyan NV. Computationally Guided Design of Single-Chain Variable Fragment Improves Specificity of Chimeric Antigen Receptors. Molecular Therapy Oncolytics. 15: 30-37. PMID 31650023 DOI: 10.1016/J.Omto.2019.08.008 |
0.402 |
|
| 2019 |
Caratelli S, Arriga R, Sconocchia T, Ottaviani A, Lanzilli G, Pastore D, Cenciarelli C, Venditti A, Del Principe MI, Lauro D, Landoni E, Du H, Savoldo B, Ferrone S, Dotti G, et al. In vitro elimination of EGFR-overexpressing cancer cells by CD32A chimeric receptor T cells in combination with cetuximab or panitumumab. International Journal of Cancer. PMID 31479522 DOI: 10.1002/Ijc.32663 |
0.395 |
|
| 2019 |
Nehama D, Di Ianni N, Musio S, Du H, Patané M, Pollo B, Finocchiaro G, Park JJH, Dunn DE, Edwards DS, Damrauer JS, Hudson H, Floyd SR, Ferrone S, Savoldo B, et al. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. Ebiomedicine. PMID 31466914 DOI: 10.1016/J.Ebiom.2019.08.030 |
0.407 |
|
| 2019 |
Peppicelli S, Ruzzolini J, Andreucci E, Bianchini F, Kontos F, Yamada T, Ferrone S, Calorini L. Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells. Cancers. 11. PMID 31454998 DOI: 10.3390/Cancers11091249 |
0.459 |
|
| 2019 |
Arriga R, Caratelli S, Lanzilli G, Ottaviani A, Cenciarelli C, Sconocchia T, Spagnoli GC, Iezzi G, Roselli M, Lauro D, Coppola A, Dotti G, Ferrone S, Sconocchia G. CD16-158-Valine Chimeric Receptor T Cells Overcome the Resistance of Kras-Mutated Colorectal Carcinoma Cells to Cetuximab. International Journal of Cancer. PMID 31396956 DOI: 10.1002/Ijc.32618 |
0.337 |
|
| 2019 |
Ascierto PA, Agarwala SS, Botti G, Budillon A, Davies MA, Dummer R, Ernstoff M, Ferrone S, Formenti S, Gajewski TF, Garbe C, Hamid O, Lo RS, Luke JJ, Michielin O, et al. Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy). Journal of Translational Medicine. 17: 234. PMID 31331337 DOI: 10.1186/S12967-019-1979-Z |
0.351 |
|
| 2019 |
Riccardo F, Tarone L, Iussich S, Giacobino D, Arigoni M, Sammartano F, Morello E, Martano M, Gattino F, Maria R, Ferrone S, Buracco P, Cavallo F. Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma. Therapeutic Advances in Medical Oncology. 11: 1758835919855491. PMID 31217827 DOI: 10.1177/1758835919855491 |
0.348 |
|
| 2019 |
Richtig G, Ramelyte E, Koch L, Greinix H, Ferrone S, Dummer R, Richtig E. Unmasking of a primary desmoplastic melanoma tumour in the course of treatment of a metastatic disease with anti-PD-1 monoclonal antibody. Journal of the European Academy of Dermatology and Venereology : Jeadv. PMID 31081948 DOI: 10.1111/Jdv.15675 |
0.338 |
|
| 2019 |
Sottile R, Federico G, Garofalo C, Tallerico R, Faniello MC, Quaresima B, Cristiani CM, Di Sanzo M, Cuda G, Ventura V, Wagner AK, Contrò G, Perrotti N, Gulletta E, Ferrone S, et al. Iron and Ferritin Modulate MHC Class I Expression and NK Cell Recognition. Frontiers in Immunology. 10: 224. PMID 30873154 DOI: 10.3389/Fimmu.2019.00224 |
0.326 |
|
| 2019 |
Kasten BB, Ferrone S, Zinn KR, Buchsbaum DJ. B7-H3-targeted radioimmunotherapy of human cancer. Current Medicinal Chemistry. PMID 30836909 DOI: 10.2174/0929867326666190228120908 |
0.361 |
|
| 2019 |
Mitra D, Horick NK, Brackett DG, Mouw KW, Hornick JL, Ferrone S, Hong TS, Mamon H, Clark JW, Parikh AR, Allen JN, Ryan DP, Ting DT, Deshpande V, Wo JY. High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. The Oncologist. PMID 30755500 DOI: 10.1634/Theoncologist.2018-0794 |
0.463 |
|
| 2019 |
Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, Tiruthani K, Mirlekar B, Michaud D, Greene K, Herrera SG, Xu Y, Sun C, Chen Y, Ma X, ... ... Ferrone S, et al. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Cancer Cell. 35: 221-237.e8. PMID 30753824 DOI: 10.1016/J.Ccell.2019.01.002 |
0.352 |
|
| 2019 |
Cai L, Michelakos T, Deshpande V, Arora KS, Yamada T, Ting DT, Taylor MS, Fernandez-Del Castillo C, Warshaw AL, Lillemoe KD, Ferrone S, Ferrone CR. Role of Tumor Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30670493 DOI: 10.1158/1078-0432.Ccr-18-1401 |
0.343 |
|
| 2019 |
Giraudo L, Gammaitoni L, Valentina B, Iaia I, Cattaneo G, Becco P, Gallo S, Zaccagna A, Pisacane A, Crotto L, Ferrone S, Aglietta M, Schianca FC, Sangiolo D. Abstract 569: Expression and modulation by IFN of HLA class I APM components in melanoma: Potential biomarkers of clinical response to checkpoint inhibitors Cancer Research. 79: 569-569. DOI: 10.1158/1538-7445.Sabcs18-569 |
0.42 |
|
| 2019 |
Sharma P, Diergaarde B, Ferrone S, Kirkwood JM, Whiteside TL. Abstract 3091: Effects of melanoma cell-derived exosomes in melanoma patients’ plasma on immune cell functions Cancer Research. 79: 3091-3091. DOI: 10.1158/1538-7445.Am2019-3091 |
0.411 |
|
| 2019 |
Riccardo F, Tarone L, Barutello G, Arigoni M, Giacobino D, Iussich S, Occhipinti S, Ferrone S, Buracco P, Cavallo F. Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumours: A comparative oncology trial Annals of Oncology. 30: v497. DOI: 10.1093/Annonc/Mdz253.043 |
0.376 |
|
| 2019 |
Kurokawa T, Kontos F, Yamada T, Wang X, Ferrone S, Ferrone CR. Immunotherapy of Intrahepatic Cholangiocarcinoma with Fc Chimeric Receptor T-Cells Journal of the American College of Surgeons. 229: S264. DOI: 10.1016/J.Jamcollsurg.2019.08.582 |
0.323 |
|
| 2018 |
Durgeau A, Virk Y, Gros G, Voilin E, Corgnac S, Djenidi F, Salmon J, Adam J, de Montpréville V, Validire P, Ferrone S, Chouaib S, Eggermont A, Soria JC, Lemonnier F, et al. Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. Nature Communications. 9: 5097. PMID 30504837 DOI: 10.1038/S41467-018-07603-1 |
0.436 |
|
| 2018 |
Sabbatino F, Marra A, Liguori L, Scognamiglio G, Fusciello C, Botti G, Ferrone S, Pepe S. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. Journal For Immunotherapy of Cancer. 6: 126. PMID 30458852 DOI: 10.1186/S40425-018-0439-2 |
0.369 |
|
| 2018 |
Ravindranath MH, Filippone EJ, Mahowald G, Callender C, Babu A, Saidman S, Ferrone S. Significance of the intraindividual variability of HLA IgG antibodies in renal disease patients observed with different beadsets monitored with two different secondary antibodies on a Luminex platform. Immunologic Research. PMID 30324227 DOI: 10.1007/S12026-018-9027-2 |
0.451 |
|
| 2018 |
Maccalli C, Rasul KI, Elawad M, Ferrone S. The role of cancer stem cells in the modulation of anti-tumor immune responses". Seminars in Cancer Biology. PMID 30261276 DOI: 10.1016/J.Semcancer.2018.09.006 |
0.4 |
|
| 2018 |
Ravindranath MH, Jucaud V, Ferrone S. Corrigendum to Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers Journal of Immunological Methods, Volume 450, Year (2017), start page 73, end page 80. Journal of Immunological Methods. 460: 125. PMID 30055839 DOI: 10.1016/J.Jim.2018.07.008 |
0.417 |
|
| 2018 |
Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, et al. Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). Journal of Translational Medicine. 16: 207. PMID 30031393 DOI: 10.1186/S12967-018-1568-6 |
0.327 |
|
| 2018 |
Pilla L, Ferrone S, Maccalli C. Methods for improving the immunogenicity and efficacy of cancer vaccines. Expert Opinion On Biological Therapy. PMID 29874943 DOI: 10.1080/14712598.2018.1485649 |
0.331 |
|
| 2018 |
Kasten BB, Gangrade A, Kim H, Fan J, Ferrone S, Ferrone CR, Zinn KR, Buchsbaum DJ. Corrigendum to 'Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models' [Nucl Med Biol 58 (2018) 67-73]. Nuclear Medicine and Biology. PMID 29705525 DOI: 10.1016/J.Nucmedbio.2018.03.004 |
0.324 |
|
| 2018 |
Eng MS, Kaur J, Prasmickaite L, Engesæter BØ, Weyergang A, Skarpen E, Berg K, Rosenblum MG, Mælandsmo GM, Høgset A, Ferrone S, Selbo PK. Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins. Photochemical & Photobiological Sciences : Official Journal of the European Photochemistry Association and the European Society For Photobiology. 17: 539-551. PMID 29565434 DOI: 10.1039/C7Pp00358G |
0.356 |
|
| 2018 |
Kasten BB, Oliver PG, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ.
Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. International Journal of Molecular Sciences. 19. PMID 29561763 DOI: 10.3390/Ijms19040925 |
0.407 |
|
| 2018 |
Sharma P, Ludwig S, Muller L, Hong CS, Kirkwood JM, Ferrone S, Whiteside TL. Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma. Journal of Extracellular Vesicles. 7: 1435138. PMID 29511460 DOI: 10.1080/20013078.2018.1435138 |
0.387 |
|
| 2018 |
Pellegatta S, Savoldo B, Di Ianni N, Corbetta C, Chen Y, Patané M, Sun C, Pollo B, Ferrone S, DiMeco F, Finocchiaro G, Dotti G. Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. Science Translational Medicine. 10. PMID 29491184 DOI: 10.1126/Scitranslmed.Aao2731 |
0.423 |
|
| 2018 |
Cai L, Michelakos T, Yamada T, Fan S, Wang X, Schwab JH, Ferrone CR, Ferrone S. Defective HLA class I antigen processing machinery in cancer. Cancer Immunology, Immunotherapy : Cii. PMID 29487978 DOI: 10.1007/S00262-018-2131-2 |
0.456 |
|
| 2018 |
Datar I, Villarroel-Espindola F, Henick BS, Syrigos KN, Toki M, Rimm DL, Ferrone S, Herbst RS, Schalper KA. Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 36: 12015-12015. DOI: 10.1200/Jco.2018.36.15_Suppl.12015 |
0.47 |
|
| 2018 |
Hastings K, Gettinger S, Jungmin C, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Schlessinger J, Goldberg S, Chiang A, Melero I, Agorreta J, ... ... Ferrone S, et al. Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancer Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A09 |
0.417 |
|
| 2018 |
Ng MR, Sabbatino F, Duquette M, Naxerova K, Badeaux M, Ferraro GB, Chin SM, Bezwada D, Brachtel EF, Ferrone S, Jain RK. Abstract LB-057: Hypoxia regulation of antigen presentation machinery expression in breast cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2018-Lb-057 |
0.313 |
|
| 2018 |
Leuci V, Rotolo R, Donini C, Mesiano G, Fiorino E, Gammaitoni L, Grignani G, D'Ambrosio L, Ferrone S, Dotti G, Aglietta M, Sangiolo D. Abstract 3591: CSPG4 as innovative target for CAR redirected CIK lymphocytes against soft tissue sarcomas Cancer Research. 78: 3591-3591. DOI: 10.1158/1538-7445.Am2018-3591 |
0.397 |
|
| 2018 |
Donisi G, Castino GF, Capretti G, Cortese N, Gavazzi F, Ridolfi C, Nappo G, Maggi G, Ferrone CR, Ferrone S, Marchesi F, Zerbi A. Tissue characterization of components of the antigen processing machinery in pancreatic ductal adenocarcinoma Pancreatology. 18: S66-S67. DOI: 10.1016/J.Pan.2018.05.179 |
0.315 |
|
| 2018 |
Kurokawa T, Yamada T, Cai L, Ferrone S, Ferrone CR. B7-H3-Specific Chimeric-Antigen Receptor T-Cell–Based Immunotherapy for Intrahepatic Cholangiocarcinoma Journal of the American College of Surgeons. 227: S236. DOI: 10.1016/J.Jamcollsurg.2018.07.622 |
0.355 |
|
| 2018 |
Lee S, Yamada T, Cai L, Michelakos T, Kurokawa T, Lee H, Ferrone S, Ferrone CR. Association of High Human Leukocyte Antigen B and C Expression Level with Prolonged Overall Survival in Colorectal Cancer Journal of the American College of Surgeons. 227: S60. DOI: 10.1016/J.Jamcollsurg.2018.07.126 |
0.357 |
|
| 2018 |
Mitra D, Horick N, Brackett D, Mouw K, Hornick J, Ferrone S, Hong T, Mamon H, Clark J, Parikh A, Ryan D, Deshpande V, Wo J. The Immune Milieu of Anal Squamous Cell Carcinoma: IDO Expression is Correlated with Poor Outcome International Journal of Radiation Oncology*Biology*Physics. 102: e13. DOI: 10.1016/J.Ijrobp.2018.07.221 |
0.319 |
|
| 2017 |
Kasten BB, Gangrade A, Kim H, Fan J, Ferrone S, Ferrone CR, Zinn KR, Buchsbaum DJ. 212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. Nuclear Medicine and Biology. 58: 67-73. PMID 29413459 DOI: 10.1016/J.Nucmedbio.2017.12.004 |
0.373 |
|
| 2017 |
Marra A, Ferrone C, Fusciello C, Scognamiglio G, Ferrone S, Pepe S, Perri F, Sabbatino F. Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. Anti-Cancer Agents in Medicinal Chemistry. PMID 29256359 DOI: 10.2174/1871520618666171219115335 |
0.305 |
|
| 2017 |
Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, et al. Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. Journal of Translational Medicine. 15: 236. PMID 29145885 DOI: 10.1186/S12967-017-1341-2 |
0.342 |
|
| 2017 |
Nicola MD, Apetoh L, Bellone M, Colombo MP, Dotti G, Ferrone S, Muscolini M, Hiscott J, Anichini A, Pupa SM, Braud F, Del Vecchio M. Innovative Therapy, Monoclonal Antibodies and Beyond. Cytokine & Growth Factor Reviews. PMID 29029813 DOI: 10.1016/J.Cytogfr.2017.10.002 |
0.45 |
|
| 2017 |
Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, ... ... Ferrone S, et al. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discovery. PMID 29025772 DOI: 10.1158/2159-8290.Cd-17-0593 |
0.372 |
|
| 2017 |
Romoli MR, Di Gennaro P, Gerlini G, Sestini S, Brandani P, Ferrone S, Borgognoni L. High Antigen Processing Machinery component expression in Langerhans cells from melanoma patients' sentinel lymph nodes. Cellular Immunology. PMID 28870403 DOI: 10.1016/J.Cellimm.2017.08.007 |
0.39 |
|
| 2017 |
Cong J, Wang Y, Zhang X, Zhang N, Liu L, Soukup K, Michelakos T, Hong T, DeLeo A, Cai L, Sabbatino F, Ferrone S, Lee H, Levina V, Fuchs B, et al. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing Disulfiram. Cancer Letters. PMID 28864067 DOI: 10.1016/J.Canlet.2017.08.028 |
0.306 |
|
| 2017 |
Wang X, Wang Y, Gu J, Zhou D, He Z, Wang X, Ferrone S. ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells. Scientific Reports. 7: 9687. PMID 28852196 DOI: 10.1038/S41598-017-10468-X |
0.302 |
|
| 2017 |
Ravindranath MH, Jucaud V, Ferrone S. Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers. Journal of Immunological Methods. PMID 28782523 DOI: 10.1016/J.Jim.2017.07.016 |
0.446 |
|
| 2017 |
Al-Sukaini A, Hornicek FJ, Peacock ZS, Kaban LB, Ferrone S, Schwab JH. Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone. Clinical Orthopaedics and Related Research. PMID 28725958 DOI: 10.1007/S11999-017-5451-1 |
0.413 |
|
| 2017 |
Ritter C, Fan K, Paschen A, Reker Hardrup S, Ferrone S, Nghiem P, Ugurel S, Schrama D, Becker JC. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Scientific Reports. 7: 2290. PMID 28536458 DOI: 10.1038/S41598-017-02608-0 |
0.442 |
|
| 2017 |
Caratelli S, Sconocchia T, Arriga R, Coppola A, Lanzilli G, Lauro D, Venditti A, Del Principe MI, Buccisano F, Maurillo L, Ferrone S, Sconocchia G. FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance. Frontiers in Immunology. 8: 457. PMID 28496440 DOI: 10.3389/Fimmu.2017.00457 |
0.43 |
|
| 2017 |
Cai L, Michelakos T, Ferrone CR, Zhang L, Deshpande V, Shen Q, De Leo A, Yamada T, Zhang G, Ferrone S, Wang X. Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. Oncotarget. PMID 28430580 DOI: 10.18632/Oncotarget.16841 |
0.332 |
|
| 2017 |
Seliger B, Kloor M, Ferrone S. HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance. Oncoimmunology. 6: e1171447. PMID 28344859 DOI: 10.1080/2162402X.2016.1171447 |
0.488 |
|
| 2017 |
Maccalli C, Parmiani G, Ferrone S. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy. Immunological Investigations. 46: 221-238. PMID 28287848 DOI: 10.1080/08820139.2017.1280051 |
0.356 |
|
| 2017 |
Kasten BB, Arend RC, Katre AA, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ. B7-H3-targeted (212)Pb radioimmunotherapy of ovarian cancer in preclinical models. Nuclear Medicine and Biology. 47: 23-30. PMID 28104527 DOI: 10.1016/J.Nucmedbio.2017.01.003 |
0.341 |
|
| 2016 |
Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, et al. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. Journal of Translational Medicine. 14: 313. PMID 27846884 DOI: 10.1186/S12967-016-1070-Y |
0.414 |
|
| 2016 |
Conteduca G, Fenoglio D, Parodi A, Battaglia F, Kalli F, Negrini S, Tardito S, Ferrera F, Salis A, Millo E, Pasquale G, Barra G, Damonte G, Indiveri F, Ferrone S, et al. AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma. Oncotarget. PMID 27563821 DOI: 10.18632/Oncotarget.11506 |
0.387 |
|
| 2016 |
Srivastava RM, Trivedi S, Concha-Benavente F, Gibson SP, Reeder C, Ferrone S, Ferris RL. CD137 stimulation enhances cetuximab induced natural killer (NK): dendritic cell (DC) priming of anti-tumor T cell immunity in head and neck cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27496866 DOI: 10.1158/1078-0432.Ccr-16-0879 |
0.452 |
|
| 2016 |
Nanda VGY, Peng W, Hwu P, Davies MA, Ciliberto G, Fattore L, Malpicci D, Aurisicchio L, Ascierto PA, Croce CM, Mancini R, Spranger S, Gajewski TF, Wang Y, Ferrone S, et al. Melanoma and Immunotherapy Bridge 2015 : Naples, Italy. 1-5 December 2015 Journal of Translational Medicine. 14: 65-65. PMID 27461275 DOI: 10.1186/S12967-016-0791-2 |
0.31 |
|
| 2016 |
Concha-Benavente F, Srivastava R, Ferrone S, Ferris RL. Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. Oral Oncology. PMID 27264839 DOI: 10.1016/J.Oraloncology.2016.05.008 |
0.451 |
|
| 2016 |
Trivedi S, Srivastava RM, Concha-Benavente F, Ferrone S, Garcia-Bates TM, Li J, Ferris RL. Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor cellular immunity in head and neck cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27217441 DOI: 10.1158/1078-0432.Ccr-15-2971 |
0.39 |
|
| 2016 |
Gameiro SR, Malamas AS, Tsang KY, Ferrone S, Hodge JW. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget. PMID 26862729 DOI: 10.18632/Oncotarget.7180 |
0.42 |
|
| 2016 |
Sabbatino F, Wang Y, Scognamiglio G, Favoino E, Feldman SA, Villani V, Flaherty KT, Nota S, Giannarelli D, Simeone E, Anniciello AM, Palmieri G, Pepe S, Botti G, Ascierto PA, ... ... Ferrone S, et al. Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma. Journal of the National Cancer Institute. 108. PMID 26851802 DOI: 10.1093/Jnci/Djv435 |
0.351 |
|
| 2016 |
Arriga R, Caratelli S, Coppola A, Spagnoli GC, Venditti A, Amadori S, Lanzilli G, Lauro D, Palomba P, Sconocchia T, Del Principe MI, Maurillo L, Buccisano F, Capuani B, Ferrone S, et al. Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage. Oncotarget. 7: 2070-9. PMID 26655503 DOI: 10.18632/Oncotarget.6529 |
0.372 |
|
| 2016 |
Gameiro SR, Malamas AS, Fantini M, Tsang KY, Ferrone S, Hodge JW. Abstract 4726: Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell-mediated lysis of prostate and breast carcinoma cells Cancer Research. 76: 4726-4726. DOI: 10.1158/1538-7445.Am2016-4726 |
0.416 |
|
| 2016 |
Sabbatino F, Wang Y, Scognamiglio G, Favoino E, Feldman SA, Villani V, Flaherty KT, Nota S, Giannarelli D, Simeone E, Anniciello AM, Palmieri G, Pepe S, Botti G, Ascierto PA, ... ... Ferrone S, et al. Abstract 4017: Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma Cancer Research. 76: 4017-4017. DOI: 10.1158/1538-7445.Am2016-4017 |
0.457 |
|
| 2016 |
Pellegatta S, Savoldo B, Su C, Ferrone S, Finocchiaro G, Dotti G. 507. Chondroitin Sulfate Proteoglycan 4 (CSPG4)-Redirected T Cells Eliminate Glioblastoma-Derived Neurospheres Molecular Therapy. 24: S202. DOI: 10.1016/S1525-0016(16)33316-0 |
0.398 |
|
| 2016 |
Cai L, Michelakos T, Fernandez-del Castillo C, Warshaw AL, Lillemoe KD, Ferrone S, Mino-Kenudson M, Ferrone CR. Potential Role of NK Cells in Progression of Intraductal Papillary Mucinous Neoplasms (IPMN) Journal of the American College of Surgeons. 223: e142-e143. DOI: 10.1016/J.Jamcollsurg.2016.08.366 |
0.319 |
|
| 2016 |
Michelakos T, Cai L, Goyal L, Zhu AX, Tanabe KK, Ferrone S, Ferrone CR. Glucose-Regulated Protein of 94kDa (Grp94)-Targeted Antibody-Based Combinatorial Immunotherapy for Intrahepatic Cholangiocarcinoma Journal of the American College of Surgeons. 223: e136-e137. DOI: 10.1016/J.Jamcollsurg.2016.08.350 |
0.314 |
|
| 2015 |
Villani V, Sabbatino F, Ferrone CR, Ferrone S. Melanoma initiating cells: where do we stand? Melanoma Management. 2: 109-114. PMID 30190839 DOI: 10.2217/Mmt.15.2 |
0.335 |
|
| 2015 |
Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, et al. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. Journal of Translational Medicine. 13: 374. PMID 26619946 DOI: 10.1186/S12967-015-0736-1 |
0.34 |
|
| 2015 |
Wang Y, Wang X, Ferrone CR, Schwab JH, Ferrone S. Intracellular antigens as targets for antibody based immunotherapy of malignant diseases. Molecular Oncology. PMID 26597109 DOI: 10.1016/J.Molonc.2015.10.019 |
0.431 |
|
| 2015 |
Sottile R, Pangigadde PN, Tan T, Anichini A, Sabbatino F, Trecroci F, Favoino E, Orgiano L, Roberts J, Ferrone S, Kärre K, Colucci F, Carbone E. HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. European Journal of Immunology. PMID 26564811 DOI: 10.1002/Eji.201445289 |
0.301 |
|
| 2015 |
Tsao CY, Sabbatino F, Cheung NV, Hsu JC, Villani V, Wang X, Ferrone S. Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells. Oncoimmunology. 4: e1023975. PMID 26405581 DOI: 10.1080/2162402X.2015.1023975 |
0.397 |
|
| 2015 |
Chang CC, Pirozzi G, Wen SH, Chung IH, Chiu BL, Errico S, Luongo M, Lombardi ML, Ferrone S. Multiple Structural and Epigenetic Defects in the Human Leukocyte Antigen class I Antigen Presentation Pathway in a Recurrent Metastatic Melanoma Following Immunotherapy. The Journal of Biological Chemistry. PMID 26381407 DOI: 10.1074/Jbc.M115.676130 |
0.456 |
|
| 2015 |
Sabbatino F, Villani V, Yearley JH, Deshpande V, Cai L, Kostantinidis IT, Moon C, Nota S, Wang Y, Al-Sukaini A, Zhu AX, Goyal L, Bardeesy N, Ting DT, Hong TS, ... ... Ferrone S, et al. PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26373575 DOI: 10.1158/1078-0432.Ccr-15-0715 |
0.489 |
|
| 2015 |
Wang Y, Geldres C, Ferrone S, Dotti G. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors. Expert Opinion On Therapeutic Targets. 1-12. PMID 26190756 DOI: 10.1517/14728222.2015.1068759 |
0.456 |
|
| 2015 |
Srivastava RM, Trivedi S, Concha-Benavente F, Hyun-Bae J, Wang L, Seethala RR, Branstetter BF, Ferrone S, Ferris RL. STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. Cancer Immunology Research. PMID 25972070 DOI: 10.1158/2326-6066.Cir-15-0053 |
0.44 |
|
| 2015 |
Jie HB, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, Whiteside TL, Ferris RL. CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Research. 75: 2200-10. PMID 25832655 DOI: 10.1158/0008-5472.Can-14-2788 |
0.436 |
|
| 2015 |
Sabbatino F, Favoino E, Wang Y, Wang X, Villani V, Cai L, Yang L, Ferrone S, Ferrone CR. Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma. Journal of Translational Medicine. 13: 2050. PMID 25779169 DOI: 10.1186/1479-5876-13-S1-K12 |
0.395 |
|
| 2015 |
Fenton M, Whiteside TL, Ferrone S, Boyiadzis M. Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts. Oncology Research. 22: 117-21. PMID 25706398 DOI: 10.3727/096504014X14174484758503 |
0.395 |
|
| 2015 |
Ruiz C, Li J, Luttgen MS, Kolatkar A, Kendall JT, Flores E, Topp Z, Samlowski WE, McClay E, Bethel K, Ferrone S, Hicks J, Kuhn P. Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. Physical Biology. 12: 016008. PMID 25574741 DOI: 10.1088/1478-3975/12/1/016008 |
0.357 |
|
| 2015 |
Surmann EM, Voigt AY, Michel S, Bauer K, Reuschenbach M, Ferrone S, von Knebel Doeberitz M, Kloor M. Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer. Cancer Immunology, Immunotherapy : Cii. 64: 357-66. PMID 25445815 DOI: 10.1007/S00262-014-1638-4 |
0.473 |
|
| 2015 |
Sconocchia G, Arriga R, Caratelli S, Lanzilli G, Coppola A, Spagnoli GC, Venditti A, Amadori S, Lauro D, Principe MID, Maurillo L, Buccisano F, Capuani B, Wang X, Ferrone S. Abstract 4050: Association of long term NK cell culture and TIMP3 over-expression with NK cell reduced susceptibility to leukemia and epithelial cancer cell induced damage Cancer Research. 75: 4050-4050. DOI: 10.1158/1538-7445.Am2015-4050 |
0.398 |
|
| 2015 |
Srivastava R, Trivedi S, Wang L, Sheethala R, Ferrone S, Branstetter B, Ferris R. 32 STAT1 regulates HLA class I upregulation and immunogenicity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients Oral Oncology. 51: e37. DOI: 10.1016/J.Oraloncology.2015.02.033 |
0.441 |
|
| 2014 |
Sconocchia G, Eppenberger S, Spagnoli GC, Tornillo L, Droeser R, Caratelli S, Ferrelli F, Coppola A, Arriga R, Lauro D, Iezzi G, Terracciano L, Ferrone S. NK cells and T cells cooperate during the clinical course of colorectal cancer. Oncoimmunology. 3: e952197. PMID 25610741 DOI: 10.4161/21624011.2014.952197 |
0.423 |
|
| 2014 |
Ali TH, Pisanti S, Ciaglia E, Mortarini R, Anichini A, Garofalo C, Tallerico R, Santinami M, Gulletta E, Ietto C, Galgani M, Matarese G, Bifulco M, Ferrone S, Colucci F, et al. Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nature Communications. 5: 5639. PMID 25472612 DOI: 10.1038/Ncomms6639 |
0.328 |
|
| 2014 |
Sabbatino F, Wang Y, Wang X, Schwab JH, Ferrone S, Ferrone CR. Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors. Seminars in Oncology. 41: 685-99. PMID 25440613 DOI: 10.1053/J.Seminoncol.2014.08.007 |
0.451 |
|
| 2014 |
Ferrone S. Therapeutic monoclonal antibodies: introduction. Seminars in Oncology. 41: 556-8. PMID 25440602 DOI: 10.1053/J.Seminoncol.2014.09.011 |
0.386 |
|
| 2014 |
Sucker A, Zhao F, Real B, Heeke C, Bielefeld N, Maβen S, Horn S, Moll I, Maltaner R, Horn PA, Schilling B, Sabbatino F, Lennerz V, Kloor M, Ferrone S, et al. Genetic evolution of T-cell resistance in the course of melanoma progression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6593-604. PMID 25294904 DOI: 10.1158/1078-0432.Ccr-14-0567 |
0.394 |
|
| 2014 |
Beard RE, Zheng Z, Lagisetty KH, Burns WR, Tran E, Hewitt SM, Abate-Daga D, Rosati SF, Fine HA, Ferrone S, Rosenberg SA, Morgan RA. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. Journal For Immunotherapy of Cancer. 2: 25. PMID 25197555 DOI: 10.1186/2051-1426-2-25 |
0.425 |
|
| 2014 |
Riccardo F, Iussich S, Maniscalco L, Lorda Mayayo S, La Rosa G, Arigoni M, De Maria R, Gattino F, Lanzardo S, Lardone E, Martano M, Morello E, Prestigio S, Fiore A, Quaglino E, ... ... Ferrone S, et al. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3753-62. PMID 24874834 DOI: 10.1158/1078-0432.Ccr-13-3042 |
0.321 |
|
| 2014 |
Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, Wang Y, Mankin H, Hornicek FJ, Duan Z. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunology Research. 2: 690-8. PMID 24866169 DOI: 10.1158/2326-6066.Cir-13-0224 |
0.364 |
|
| 2014 |
Sabbatino F, Wang Y, Wang X, Flaherty KT, Yu L, Pepin D, Scognamiglio G, Pepe S, Kirkwood JM, Cooper ZA, Frederick DT, Wargo JA, Ferrone S, Ferrone CR. PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget. 5: 1926-41. PMID 24732172 DOI: 10.18632/Oncotarget.1878 |
0.328 |
|
| 2014 |
Della Vittoria Scarpati G, Fusciello C, Perri F, Sabbatino F, Ferrone S, Carlomagno C, Pepe S. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Oncotargets and Therapy. 7: 203-9. PMID 24570590 DOI: 10.2147/Ott.S57335 |
0.432 |
|
| 2014 |
Sconocchia G, Eppenberger-Castori S, Zlobec I, Karamitopoulou E, Arriga R, Coppola A, Caratelli S, Spagnoli GC, Lauro D, Lugli A, Han J, Iezzi G, Ferrone C, Ferlosio A, Tornillo L, ... ... Ferrone S, et al. HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. Neoplasia (New York, N.Y.). 16: 31-42. PMID 24563618 DOI: 10.1593/Neo.131568 |
0.471 |
|
| 2014 |
Morandi F, Di Carlo E, Ferrone S, Petretto A, Pistoia V, Airoldi I. IL-27 in human secondary lymphoid organs attracts myeloid dendritic cells and impairs HLA class I-restricted antigen presentation. Journal of Immunology (Baltimore, Md. : 1950). 192: 2634-42. PMID 24554774 DOI: 10.4049/Jimmunol.1302656 |
0.319 |
|
| 2014 |
Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 5: 403-16. PMID 24480782 DOI: 10.18632/Oncotarget.1719 |
0.388 |
|
| 2014 |
Geldres C, Savoldo B, Hoyos V, Caruana I, Zhang M, Yvon E, Del Vecchio M, Creighton CJ, Ittmann M, Ferrone S, Dotti G. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 962-71. PMID 24334762 DOI: 10.1158/1078-0432.Ccr-13-2218 |
0.421 |
|
| 2014 |
Volonté A, Di Tomaso T, Spinelli M, Todaro M, Sanvito F, Albarello L, Bissolati M, Ghirardelli L, Orsenigo E, Ferrone S, Doglioni C, Stassi G, Dellabona P, Staudacher C, Parmiani G, et al. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. Journal of Immunology (Baltimore, Md. : 1950). 192: 523-32. PMID 24277698 DOI: 10.4049/Jimmunol.1301342 |
0.425 |
|
| 2014 |
Wang Y, Sabbatino F, Wang X, Ferrone S. Detection of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma. Methods in Molecular Biology (Clifton, N.J.). 1102: 523-35. PMID 24258997 DOI: 10.1007/978-1-62703-727-3_28 |
0.43 |
|
| 2014 |
Fauci JM, Sabbatino F, Wang Y, Londoño-Joshi AI, Straughn JM, Landen CN, Ferrone S, Buchsbaum DJ. Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecologic Oncology. 132: 203-10. PMID 24216048 DOI: 10.1016/J.Ygyno.2013.10.038 |
0.421 |
|
| 2014 |
Sabbatino F, Milham L, Deshpande V, Konstantinidis IT, Zhu AX, Santos DD, Bardeesy N, Hong TS, Tanabe K, Ferrone S, Lillemoe K, Ferrone C. Variability in immune infiltrates and HLA expression in cholangiocarcinoma. Journal of Clinical Oncology. 32: 230-230. DOI: 10.1200/Jco.2014.32.3_Suppl.230 |
0.467 |
|
| 2014 |
Ascierto PA, Flaherty K, Queirolo P, Sullivan RJ, Chiarion-Sileni V, Ridolfi R, Testori A, Simeone E, Grimaldi AM, Sabbatino F, Curvietto M, Ciliberto G, Botti G, Mozzillo N, Ferrone S. Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation. Journal of Clinical Oncology. 32: TPS9105-TPS9105. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps9105 |
0.39 |
|
| 2014 |
Sconocchia G, Arriga R, Caratelli S, Coppola A, Spagnoli G, Lanzilli G, Capuani B, Ferrelli F, Lauro D, Ferrone S. P16. Differential susceptibility of human and mouse NK cells to malignant cell-induced abnormalities in autologous combinations: a potential mechanism for the NK cell-based immunotherapy efficacy Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S2-P7 |
0.378 |
|
| 2014 |
Ali T, Pisanti S, Ciaglia E, Mortarini R, Anichini A, Santinami M, Gulletta E, Ietto C, Galgani M, Garofalo C, Matarese G, Bifulco M, Ferrone S, Colucci F, Moretta A, et al. Enrichment of KIR+CD57+ highly cytotoxic NK cells in sentinel lymph nodes of melanoma patients Journal of Translational Medicine. 12: P10. DOI: 10.1186/1479-5876-12-S1-P10 |
0.337 |
|
| 2014 |
Tan T, Pangigadde P, Sabbatino F, Favoino E, Orgiano L, Ferrone S, Carbone E, Colucci F. Harnessing host innate immunity may combat acquired resistance to BRAFi Journal of Translational Medicine. 12: O10. DOI: 10.1186/1479-5876-12-S1-O10 |
0.344 |
|
| 2014 |
Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing Cancer Research. 74: 632-632. DOI: 10.1158/1538-7445.Am2014-632 |
0.392 |
|
| 2014 |
Sabbatino F, Wang Y, Wang X, Flaherty KT, Pepin D, Scognamiglio G, Yu L, Cooper ZA, Pepe S, Kirkwood JM, Frederick DT, Wargo JA, Ferrone S, Ferrone CR. Abstract 3703: PDGFRα up-regulation mediated by Sonic Hedgehog Pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation Cancer Research. 74: 3703-3703. DOI: 10.1158/1538-7445.Am2014-3703 |
0.335 |
|
| 2014 |
Wang Y, Patel SS, Cong J, Zhang N, Qi Y, Sabbatino F, Isakoff S, DeLeo AB, Ferrone S, Wang X. Abstract 3639: Combinatorial therapy for triple negative breast cancer Cancer Research. 74: 3639-3639. DOI: 10.1158/1538-7445.Am2014-3639 |
0.374 |
|
| 2013 |
Sabbatino F, Schwab JH, Ferrone S, Ferrone CR. Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells. Clinical Transplants. 453-63. PMID 25095541 |
0.389 |
|
| 2013 |
Concha-Benavente F, Srivastava RM, Ferrone S, Ferris RL. EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3. Oncoimmunology. 2: e27215. PMID 24501692 DOI: 10.4161/Onci.27215 |
0.315 |
|
| 2013 |
Morandi B, Bonaccorsi I, Mesiti M, Conte R, Carrega P, Costa G, Iemmo R, Martini S, Ferrone S, Cantoni C, Mingari MC, Moretta L, Ferlazzo G. Characterization of human afferent lymph dendritic cells from seroma fluids Journal of Immunology. 191: 4858-4866. PMID 24078697 DOI: 10.4049/Jimmunol.1300760 |
0.308 |
|
| 2013 |
Eisenberg G, Uzana R, Pato A, Frankenburg S, Merims S, Yefenof E, Ferrone S, Peretz T, Machlenkin A, Lotem M. Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells. Journal of Immunology (Baltimore, Md. : 1950). 190: 5856-65. PMID 23626012 DOI: 10.4049/Jimmunol.1202879 |
0.415 |
|
| 2013 |
Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, López-Albaitero A, Gibson SP, Gooding WE, Ferrone S, Ferris RL. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1858-72. PMID 23444227 DOI: 10.1158/1078-0432.Ccr-12-2426 |
0.486 |
|
| 2013 |
Schilling B, Harasymczuk M, Schuler P, Egan J, Ferrone S, Whiteside TL. IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cells. Plos One. 8: e47234. PMID 23408925 DOI: 10.1371/Journal.Pone.0047234 |
0.443 |
|
| 2013 |
Yeung JT, Hamilton RL, Ohnishi K, Ikeura M, Potter DM, Nikiforova MN, Ferrone S, Jakacki RI, Pollack IF, Okada H. LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1816-26. PMID 23401227 DOI: 10.1158/1078-0432.Ccr-12-2861 |
0.402 |
|
| 2013 |
Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. International Journal of Cancer. Journal International Du Cancer. 133: 624-36. PMID 23364915 DOI: 10.1186/2051-1426-1-S1-P91 |
0.424 |
|
| 2013 |
Leibowitz MS, Srivastava RM, Andrade Filho PA, Egloff AM, Wang L, Seethala RR, Ferrone S, Ferris RL. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 798-808. PMID 23363816 DOI: 10.1158/1078-0432.Ccr-12-1517 |
0.487 |
|
| 2013 |
Loustau M, Wiendl H, Ferrone S, Carosella ED. HLA-G 2012 conference: the 15-year milestone update. Tissue Antigens. 81: 127-36. PMID 23347068 DOI: 10.1111/Tan.12053 |
0.355 |
|
| 2013 |
Sabbatino F, Ferrone S. Can the "right" EGFR-specific mAb dramatically improve EGFR-targeted therapy? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 958-60. PMID 23340298 DOI: 10.1158/1078-0432.Ccr-12-3586 |
0.366 |
|
| 2013 |
Wastowski IJ, Simões RT, Yaghi L, Donadi EA, Pancoto JT, Poras I, Lechapt-Zalcman E, Bernaudin M, Valable S, Carlotti CG, Flajollet S, Jensen SS, Ferrone S, Carosella ED, Kristensen BW, et al. Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study. The American Journal of Pathology. 182: 540-52. PMID 23219427 DOI: 10.1016/J.Ajpath.2012.10.021 |
0.379 |
|
| 2013 |
Grizzi F, Franceschini B, Biccari SD, Bossi P, Chiriva-Internati M, Ferrone S. High frequency of HLA class I antigen processing machinery (APM) component upregulation in primary hepatocellular carcinoma tumors Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P264 |
0.413 |
|
| 2013 |
Srivastava RM, Jie H, Ferrone S, Ferris RL. STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P175 |
0.426 |
|
| 2013 |
Wang Y, Sabbatino F, Ferrone S, Wang X. Abstract 4741: Inhibition of TNBC cell growth by CSPG4-specific mAb 225.28 with a Sonic Hedgehog pathway inhibitor Cancer Research. 73: 4741-4741. DOI: 10.1158/1538-7445.Am2013-4741 |
0.398 |
|
| 2013 |
Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang K, Ferrone S, Gameiro SR. Abstract 1676: Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Cancer Research. 73: 1676-1676. DOI: 10.1158/1538-7445.Am2013-1676 |
0.422 |
|
| 2012 |
Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, Spagnoli GC. Melanoma cells inhibit NK cell functions. Cancer Research. 72: 5428-9; author reply. PMID 23047870 DOI: 10.1158/0008-5472.Can-12-1181 |
0.37 |
|
| 2012 |
Fauci JM, Straughn JM, Ferrone S, Buchsbaum DJ. A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecologic Oncology. 127: 420-5. PMID 22910694 DOI: 10.1016/J.Ygyno.2012.08.017 |
0.313 |
|
| 2012 |
Rivera Z, Ferrone S, Wang X, Jube S, Yang H, Pass HI, Kanodia S, Gaudino G, Carbone M. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5352-63. PMID 22893632 DOI: 10.1158/1078-0432.Ccr-12-0628 |
0.395 |
|
| 2012 |
Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. Ca: a Cancer Journal For Clinicians. 62: 309-35. PMID 22576456 DOI: 10.3322/Caac.20132 |
0.345 |
|
| 2012 |
Tassi E, Zanon M, Vegetti C, Molla A, Bersani I, Perotti V, Pennati M, Zaffaroni N, Milella M, Ferrone S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A. Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3316-27. PMID 22553342 DOI: 10.1158/1078-0432.Ccr-11-2232 |
0.357 |
|
| 2012 |
Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, et al. Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". Journal of Translational Medicine. 10: 83. PMID 22551296 DOI: 10.1186/1479-5876-10-83 |
0.305 |
|
| 2012 |
Campoli M, Fitzpatrick JE, High W, Ferrone S. HLA antigen expression in melanocytic lesions: is acquisition of HLA antigen expression a biomarker of atypical (dysplastic) melanocytes? Journal of the American Academy of Dermatology. 66: 911-6, 916.e1-8. PMID 22445792 DOI: 10.1016/J.Jaad.2011.04.025 |
0.405 |
|
| 2012 |
Favole A, Cascio P, Cerruti F, Sereno A, Tursi M, Tomatis A, Della Beffa C, Ferrone S, Bollo E. MHC class I-related antigen-processing machinery component defects in feline mammary carcinoma. Translational Oncology. 5: 48-55. PMID 22348176 DOI: 10.1593/Tlo.11247 |
0.477 |
|
| 2012 |
Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, Saida T, Ferrone S, Takata M, Uhara H, Okuyama R. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. British Journal of Cancer. 106: 939-46. PMID 22281663 DOI: 10.1038/Bjc.2012.12 |
0.375 |
|
| 2012 |
Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV. Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunology, Immunotherapy : Cii. 61: 1243-53. PMID 22258792 DOI: 10.1007/S00262-012-1201-0 |
0.387 |
|
| 2012 |
Tanaka K, Tsuchikawa T, Miyamoto M, Maki T, Ichinokawa M, Kubota KC, Shichinohe T, Hirano S, Ferrone S, Dosaka-Akita H, Matsuno Y, Kondo S. Down-regulation of Human Leukocyte Antigen class I heavy chain in tumors is associated with a poor prognosis in advanced esophageal cancer patients. International Journal of Oncology. 40: 965-74. PMID 22134332 DOI: 10.3892/Ijo.2011.1274 |
0.421 |
|
| 2012 |
Liu Y, Komohara Y, Domenick N, Ohno M, Ikeura M, Hamilton RL, Horbinski C, Wang X, Ferrone S, Okada H. Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunology, Immunotherapy : Cii. 61: 789-801. PMID 22065046 DOI: 10.1007/S00262-011-1137-9 |
0.348 |
|
| 2012 |
Favole A, Cascio P, Cerruti F, Sereno A, Tursi M, Tomatis A, Beffa CD, Ferrone S, Bollo E. MHC class I-related antigen-processing machinery component defects in feline mammary carcinoma Translational Oncology. 5: 48-55. DOI: 10.1593/tlo.11247 |
0.372 |
|
| 2012 |
Krauze MT, Hamilton RH, Romkes M, Bortoluzzi S, Harasymczuk M, Reinhard T, Junecko BF, Nukui T, Konstantinopoulos P, Becker D, Kondziolka D, Tarhini AA, Whiteside T, Mintz AH, Tawbi H, ... Ferrone S, et al. Association of high T-cell immune infiltrate and low hemorrhage in melanoma brain metastases (MBMs) with prolonged survival. Journal of Clinical Oncology. 30: 8528-8528. DOI: 10.1200/Jco.2012.30.15_Suppl.8528 |
0.351 |
|
| 2012 |
McGregor JR, Samlowski WE, Tharkar S, Donepudi S, Ferrone S. Isolation and expansion of circulating tumor cells (CTC) from melanoma patients using a novel cell culture technique. Journal of Clinical Oncology. 30: 10614-10614. DOI: 10.1200/Jco.2012.30.15_Suppl.10614 |
0.377 |
|
| 2012 |
Lord CA, Srivastava RM, Lee SC, Filho PAA, Gibson SP, Gooding WE, Ferrone S, Ferris RL. Abstract LB-431: Augmented induction of tumor antigen-specific CTL by cetuximab in head and neck cancer patients does not correlate with Fcγ receptor IIIa genotype, but relies on NK:DC cross talk mediated by interferon-γ and NKG2D Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-431 |
0.434 |
|
| 2012 |
Wang Y, Favoino E, Yu L, Ferrone CR, Ferrone S, Wang X. Abstract 4390: Heat shock protein (HSP) Grp94-targeted combinatorial immunotherapy for pancreatic cancer Cancer Research. 72: 4390-4390. DOI: 10.1158/1538-7445.Am2012-4390 |
0.399 |
|
| 2012 |
Zeyana R, Ferrone S, Wang X, Sandro J, Yang H, Gaudino G, Carbone M. Abstract 2514: CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma Cancer Research. 72: 2514-2514. DOI: 10.1158/1538-7445.Am2012-2514 |
0.416 |
|
| 2012 |
Schilling B, Fourcade J, Ferrone S, Whiteside TL. Abstract 1574: Quantitation of HLA-A2-MAGE3271-279complexes on the DC surface improves anticancer vaccine designs Cancer Research. 72: 1574-1574. DOI: 10.1158/1538-7445.Am2012-1574 |
0.385 |
|
| 2011 |
Wang X, Katayama A, Wang Y, Yu L, Favoino E, Sakakura K, Favole A, Tsuchikawa T, Silver S, Watkins SC, Kageshita T, Ferrone S. Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Research. 71: 7410-22. PMID 22021902 DOI: 10.1158/0008-5472.Can-10-1134 |
0.481 |
|
| 2011 |
Price MA, Colvin Wanshura LE, Yang J, Carlson J, Xiang B, Li G, Ferrone S, Dudek AZ, Turley EA, McCarthy JB. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell & Melanoma Research. 24: 1148-57. PMID 22004131 DOI: 10.1111/J.1755-148X.2011.00929.X |
0.379 |
|
| 2011 |
Ferrone S. Hidden immunotherapy targets challenge dogma. Science Translational Medicine. 3: 99ps38. PMID 21900591 DOI: 10.1126/Scitranslmed.3002821 |
0.383 |
|
| 2011 |
Visus C, Wang Y, Lozano-Leon A, Ferris RL, Silver S, Szczepanski MJ, Brand RE, Ferrone CR, Whiteside TL, Ferrone S, DeLeo AB, Wang X. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6174-84. PMID 21856769 DOI: 10.1158/1078-0432.Ccr-11-1111 |
0.438 |
|
| 2011 |
Lee SC, Srivastava RM, López-Albaitero A, Ferrone S, Ferris RL. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunologic Research. 50: 248-54. PMID 21717064 DOI: 10.1007/S12026-011-8231-0 |
0.47 |
|
| 2011 |
Morandi F, Corrias MV, Levreri I, Scaruffi P, Raffaghello L, Carlini B, Bocca P, Prigione I, Stigliani S, Amoroso L, Ferrone S, Pistoia V. Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients. Cancer Immunology, Immunotherapy : Cii. 60: 1485-95. PMID 21660451 DOI: 10.1007/S00262-011-1052-0 |
0.414 |
|
| 2011 |
Zarour HM, Ferrone S. Cancer immunotherapy: Progress and challenges in the clinical setting. European Journal of Immunology. 41: 1510-5. PMID 21618503 DOI: 10.1002/Eji.201190035 |
0.435 |
|
| 2011 |
Latzka J, Gaier S, Hofstetter G, Balazs N, Smole U, Ferrone S, Scheiner O, Breiteneder H, Pehamberger H, Wagner S. Specificity of mimotope-induced anti-high molecular weight-melanoma associated antigen (HMW-MAA) antibodies does not ensure biological activity. Plos One. 6: e19383. PMID 21573118 DOI: 10.1371/Journal.Pone.0019383 |
0.459 |
|
| 2011 |
Campoli M, Ferrone S. HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Seminars in Immunopathology. 33: 321-34. PMID 21523560 DOI: 10.1007/S00281-011-0270-Z |
0.5 |
|
| 2011 |
Mayayo SL, Prestigio S, Maniscalco L, La Rosa G, Aricò A, De Maria R, Cavallo F, Ferrone S, Buracco P, Iussich S. Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma. Veterinary Journal (London, England : 1997). 190: e26-30. PMID 21482159 DOI: 10.1016/J.Tvjl.2011.02.020 |
0.447 |
|
| 2011 |
Respa A, Bukur J, Ferrone S, Pawelec G, Zhao Y, Wang E, Marincola FM, Seliger B. Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2668-78. PMID 21248298 DOI: 10.1158/1078-0432.Ccr-10-2114 |
0.435 |
|
| 2011 |
Leibowitz MS, Andrade Filho PA, Ferrone S, Ferris RL. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunology, Immunotherapy : Cii. 60: 525-35. PMID 21207025 DOI: 10.1007/S00262-010-0961-7 |
0.403 |
|
| 2011 |
Amiot L, Ferrone S, Grosse-Wilde H, Seliger B. Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Cellular and Molecular Life Sciences : Cmls. 68: 417-31. PMID 21063893 DOI: 10.1007/S00018-010-0583-4 |
0.416 |
|
| 2011 |
Brady MT, Lee J, Ferrone S, Wang ES, Wetzler M. Interferon-γ secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells. Leukemia Research. 35: 275-7. PMID 20943267 DOI: 10.1016/J.Leukres.2010.09.003 |
0.353 |
|
| 2011 |
Chikamatsu K, Takahashi G, Sakakura K, Ferrone S, Masuyama K. Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck. Head & Neck. 33: 208-15. PMID 20848440 DOI: 10.1002/Hed.21420 |
0.411 |
|
| 2011 |
Fenton M, Gasparetto M, Hong C, Wang X, Smith C, Whiteside T, Ferrone S, Boyiadzis M. Identification of Chondroitin Sulfate Proteoglycan-4 In Acute Myeloid Leukemia Using Monoclonal Antibody 225.28 Blood. 118: 4885-4885. DOI: 10.1182/Blood.V118.21.4885.4885 |
0.468 |
|
| 2011 |
Zeyana R, Ferrone S, Wang X, Jube S, Yang H, Gaudino G, Carbone M. Abstract 4579: CSPG4 monoclonal antibodies inhibit the growth of human malignant mesothelioma Cancer Research. 71: 4579-4579. DOI: 10.1158/1538-7445.Am2011-4579 |
0.427 |
|
| 2011 |
Liu Y, Komohara Y, Domenick N, Horbinski C, Hamilton R, Ferrone S, Okada H. Abstract 2439: Association of antigen processing machinery components and CD8+ T-cell infiltration in breast cancer brain metastasis Cancer Research. 71: 2439-2439. DOI: 10.1158/1538-7445.Am2011-2439 |
0.335 |
|
| 2010 |
Campoli M, Ferrone S, Wang X. Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Advances in Cancer Research. 109: 73-121. PMID 21070915 DOI: 10.1016/B978-0-12-380890-5.00003-X |
0.469 |
|
| 2010 |
Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, Brufsky A, Chivukula M, Khoury T, Hsu DS, Barry WT, Lyerly HK, Clay TM, Ferrone S. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. Journal of the National Cancer Institute. 102: 1496-512. PMID 20852124 DOI: 10.1093/Jnci/Djq343 |
0.415 |
|
| 2010 |
Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4390-9. PMID 20697078 DOI: 10.1200/Jco.2009.27.6360 |
0.441 |
|
| 2010 |
Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, Ferrone CR, Favoino E, Koya Y, Campoli MR, McCarthy JB, DeLeo AB, Ferrone S. CSPG4 in cancer: multiple roles. Current Molecular Medicine. 10: 419-29. PMID 20455858 DOI: 10.2174/156652410791316977 |
0.46 |
|
| 2010 |
Mine T, Matsueda S, Gao H, Li Y, Wong KK, Peoples GE, Ferrone S, Ioannides CG. Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells. Oncology Reports. 23: 1537-43. PMID 20428807 DOI: 10.3892/Or_00000793 |
0.313 |
|
| 2010 |
Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, Feldman SA, Ferrone S, Rosenberg SA, Morgan RA. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Research. 70: 3027-33. PMID 20395199 DOI: 10.1158/0008-5472.Can-09-2824 |
0.52 |
|
| 2010 |
Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, Mortini P, Ferrone S, Doglioni C, Marincola FM, Galli R, Parmiani G, Maccalli C. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 800-13. PMID 20103663 DOI: 10.1158/1078-0432.Ccr-09-2730 |
0.467 |
|
| 2010 |
Karyampudi L, Formicola C, Erskine CL, Maurer MJ, Ingle JN, Krco CJ, Wettstein PJ, Kalli KR, Fikes JD, Beebe M, Hartmann LC, Disis ML, Ferrone S, Ishioka G, Knutson KL. A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 825-34. PMID 20103660 DOI: 10.1158/1078-0432.Ccr-09-2781 |
0.452 |
|
| 2010 |
Campoli M, Ferris R, Ferrone S, Wang X. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 11-20. PMID 20028761 DOI: 10.1158/1078-0432.Ccr-09-2345 |
0.487 |
|
| 2010 |
Michel S, Linnebacher M, Alcaniz J, Voss M, Wagner R, Dippold W, Becker C, von Knebel Doeberitz M, Ferrone S, Kloor M. Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. International Journal of Cancer. Journal International Du Cancer. 127: 889-98. PMID 20013806 DOI: 10.1002/Ijc.25106 |
0.415 |
|
| 2010 |
Racanelli V, Leone P, Frassanito MA, Brunetti C, Perosa F, Ferrone S, Dammacco F. Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood. 115: 1185-93. PMID 20008301 DOI: 10.1182/Blood-2009-06-228676 |
0.382 |
|
| 2010 |
Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, Tannapfel A, Hofstaedter F, Hartmann A. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunology, Immunotherapy : Cii. 59: 529-40. PMID 19820934 DOI: 10.1007/S00262-009-0769-5 |
0.41 |
|
| 2010 |
Cathro HP, Smolkin ME, Theodorescu D, Jo VY, Ferrone S, Frierson HF. Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. Cancer Immunology, Immunotherapy : Cii. 59: 465-72. PMID 19756593 DOI: 10.1007/S00262-009-0765-9 |
0.376 |
|
| 2010 |
Meyer Zu Horste G, Heidenreich H, Lehmann HC, Ferrone S, Hartung HP, Wiendl H, Kieseier BC. Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies. Glia. 58: 80-92. PMID 19544394 DOI: 10.1002/Glia.20903 |
0.483 |
|
| 2010 |
Masucci GV, Andersson E, Villabona L, Helgadottir H, Bergfeldt K, Cavallo F, Forni G, Ferrone S, Choudhury A, Seliger B, Kiessling R. Survival of the fittest or best adapted: HLA-dependent tumor development Journal of Nucleic Acids Investigation. 1: 9. DOI: 10.4081/Jnai.2010.1654 |
0.415 |
|
| 2010 |
Visús C, Wang Y, Szczepanski MJ, Ferris RL, Whiteside TL, Ferrone S, Wang X, DeLeo AB. Abstract 5605: Targeting cancer stem cells in squamous cell carcinoma of the head and neck with combinatorial adoptive immunotherapy Cancer Research. 70: 5605-5605. DOI: 10.1158/1538-7445.Am10-5605 |
0.463 |
|
| 2010 |
Wang Z, Johnson DE, Cui N, Wu X, Herberman R, Ferrone S, Wang W. Abstract 5384: Tanshinone IIA synergizes with arsenic trioxide to promote human NB4 promyelocytic leukemia cell differentiation and apoptosis Cancer Research. 70: 5384-5384. DOI: 10.1158/1538-7445.Am10-5384 |
0.379 |
|
| 2010 |
Chikamatsu K, Takahashi G, Sakakura K, Ferrone S, Masuyama K. Abstract 5314: Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck Cancer Research. 70: 5314-5314. DOI: 10.1158/1538-7445.Am10-5314 |
0.369 |
|
| 2010 |
Wang Y, Yu L, Deng X, Koya T, Ferrone S, Wang X. Abstract 4408: Prevention of post surgery tumor recurrence and metastasis of melanoma by a fully human CSPG4-specific antibody Cancer Research. 70: 4408-4408. DOI: 10.1158/1538-7445.Am10-4408 |
0.428 |
|
| 2010 |
Zeyana R, Ferrone S, Yang H, Wang X, Carbone M. Abstract 2323: Inhibition of in vitro growth of human mesothelioma cells by CSPG4-specific monoclonal antibodies Cancer Research. 70: 2323-2323. DOI: 10.1158/1538-7445.Am10-2323 |
0.421 |
|
| 2010 |
Wang Z, Cui N, Ferrone S, Wu X, Herberman R, Wang W. Abstract 1891: Tanshinone IIA is a novel agent for melanoma prevention and therapy Cancer Research. 70: 1891-1891. DOI: 10.1158/1538-7445.Am10-1891 |
0.424 |
|
| 2009 |
Yang J, Price MA, Li GY, Bar-Eli M, Salgia R, Jagedeeswaran R, Carlson JH, Ferrone S, Turley EA, McCarthy JB. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Research. 69: 7538-47. PMID 19738072 DOI: 10.1158/0008-5472.Can-08-4626 |
0.348 |
|
| 2009 |
López-Albaitero A, Mailliard R, Hackman T, Andrade Filho PA, Wang X, Gooding W, Ferrone S, Kalinski P, Ferris RL. Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function. Journal of Immunotherapy (Hagerstown, Md. : 1997). 32: 465-73. PMID 19609238 DOI: 10.1097/Cji.0B013E3181A1C24E |
0.379 |
|
| 2009 |
Sconocchia G, Spagnoli GC, Del Principe D, Ferrone S, Anselmi M, Wongsena W, Cervelli V, Schultz-Thater E, Wyler S, Carafa V, Moch H, Terracciano L, Tornillo L. Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction. Neoplasia (New York, N.Y.). 11: 662-71. PMID 19568411 DOI: 10.1593/Neo.09296 |
0.386 |
|
| 2009 |
Shen Y, Xia M, Zhang J, Xu L, Yang J, Chen A, Miao F, Ferrone S, Xie W. IRF-1 and p65 mediate upregulation of constitutive HLA-A antigen expression by hepatocellular carcinoma cells. Molecular Immunology. 46: 2045-53. PMID 19428110 DOI: 10.1016/J.Molimm.2009.03.001 |
0.383 |
|
| 2009 |
Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. Journal of Immunology (Baltimore, Md. : 1950). 182: 5240-9. PMID 19380770 DOI: 10.4049/Jimmunol.0803245 |
0.316 |
|
| 2009 |
Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A, Pende D, Groh V, Biassoni R, Höglund P, Kato M, ... ... Ferrone S, et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. The Journal of Clinical Investigation. 119: 1251-63. PMID 19349689 DOI: 10.1172/Jci36022 |
0.42 |
|
| 2009 |
La Rocca R, Fulciniti M, Lakshmikanth T, Mesuraca M, Ali TH, Mazzei V, Amodio N, Catalano L, Rotoli B, Ouerfelli O, Grieco M, Gulletta E, Bond HM, Morrone G, Ferrone S, et al. Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells Journal of Immunology. 182: 4529-4537. PMID 19342626 DOI: 10.4049/Jimmunol.0802109 |
0.448 |
|
| 2009 |
López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunology, Immunotherapy : Cii. 58: 1853-64. PMID 19319529 DOI: 10.1007/S00262-009-0697-4 |
0.428 |
|
| 2009 |
Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet (London, England). 373: 1033-40. PMID 19304016 DOI: 10.1016/S0140-6736(09)60251-8 |
0.44 |
|
| 2009 |
Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Research. 69: 2887-95. PMID 19276366 DOI: 10.1158/0008-5472.Can-08-3343 |
0.351 |
|
| 2009 |
Kitago M, Koyanagi K, Nakamura T, Goto Y, Faries M, O'Day SJ, Morton DL, Ferrone S, Hoon DS. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clinical Chemistry. 55: 757-64. PMID 19233913 DOI: 10.1373/Clinchem.2008.116467 |
0.476 |
|
| 2009 |
Paul AK, Ciesielski MJ, Sajjad M, Wang X, Ferrone S, Abdel-Nabi H, Fenstermaker RA. Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting. Journal of Neuro-Oncology. 94: 21-30. PMID 19152070 DOI: 10.1007/S11060-009-9798-3 |
0.421 |
|
| 2009 |
Wongsena W, Sconocchia G, Cho HS, Chang CC, Wang X, Klumkrathok K, Ferrone S, Leelayuwat C. Production and characterization of monoclonal antibodies against major histocompatibility complex class I chain-related gene A. Tissue Antigens. 72: 431-40. PMID 18937790 DOI: 10.1111/J.1399-0039.2008.01118.X |
0.478 |
|
| 2009 |
Verheyden S, Ferrone S, Mulder A, Claas FH, Schots R, De Moerloose B, Benoit Y, Demanet C. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells. Cancer Immunology, Immunotherapy : Cii. 58: 855-65. PMID 18841361 DOI: 10.1007/S00262-008-0601-7 |
0.452 |
|
| 2009 |
Drake AS, Brady MT, Wang XH, Sait SJ, Earp JC, Ghoshal Gupta S, Ferrone S, Wang ES, Wetzler M. Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies. Cancer Immunology, Immunotherapy : Cii. 58: 415-27. PMID 18677475 DOI: 10.1007/S00262-008-0567-5 |
0.441 |
|
| 2009 |
Schwab JH, Boland PJ, Agaram NP, Socci ND, Guo T, O'Toole GC, Wang X, Ostroumov E, Hunter CJ, Block JA, Doty S, Ferrone S, Healey JH, Antonescu CR. Chordoma and chondrosarcoma gene profile: implications for immunotherapy. Cancer Immunology, Immunotherapy : Cii. 58: 339-49. PMID 18641983 DOI: 10.1007/S00262-008-0557-7 |
0.349 |
|
| 2009 |
Vujanovic L, Whiteside TL, Potter DM, Chu J, Ferrone S, Butterfield LH. Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. Cancer Immunology, Immunotherapy : Cii. 58: 121-33. PMID 18488218 DOI: 10.1007/S00262-008-0533-2 |
0.443 |
|
| 2009 |
Wang X, Osada T, Wang Y, Miyazato P, Thorne S, DeLeo A, Lyerly H, Clay T, Ferrone S. Antibody-based immunotherapy: targeting CSPG4 on human basal breast cancer stem cells. Cancer Research. 69: 5046. DOI: 10.1158/0008-5472.Sabcs-5046 |
0.33 |
|
| 2008 |
Mine T, Matsueda S, Li Y, Tokumitsu H, Gao H, Danes C, Wong KK, Wang X, Ferrone S, Ioannides CG. Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells. Cancer Immunology, Immunotherapy : Cii. 58: 1185-94. PMID 19048252 DOI: 10.1007/S00262-008-0623-1 |
0.341 |
|
| 2008 |
Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, Morton DL, Irie RF, Hoon DS. Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Molecular Cancer Therapeutics. 7: 3642-53. PMID 19001446 DOI: 10.1158/1535-7163.Mct-08-0582 |
0.317 |
|
| 2008 |
Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends in Molecular Medicine. 14: 550-9. PMID 18986838 DOI: 10.1016/J.Molmed.2008.09.010 |
0.383 |
|
| 2008 |
Campoli M, Ferrone S. HLA antigen changes in malignant cells: Epigenetic mechanisms and biologic significance Oncogene. 27: 5869-5885. PMID 18836468 DOI: 10.1038/Onc.2008.273 |
0.5 |
|
| 2008 |
Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Research. 68: 8066-75. PMID 18829565 DOI: 10.1158/0008-5472.Can-08-0287 |
0.451 |
|
| 2008 |
Tourkova IL, Shurin GV, Ferrone S, Shurin MR. Interferon regulatory factor 8 mediates tumor-induced inhibition of antigen processing and presentation by dendritic cells. Cancer Immunology, Immunotherapy : Cii. 58: 567-74. PMID 18751977 DOI: 10.1007/S00262-008-0579-1 |
0.442 |
|
| 2008 |
Hsieh CH, Hsu YJ, Chang CC, Liu HC, Chuang KL, Chuang CK, Pang ST, Hasumi K, Ferrone S, Liao SK. Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta2-microglobulin genes. Cancer Immunology, Immunotherapy : Cii. 58: 395-408. PMID 18704411 DOI: 10.1007/S00262-008-0565-7 |
0.395 |
|
| 2008 |
Campoli M, Ferrone S. Tumor escape mechanisms: Potential role of soluble HLA antigens and NK cells activating ligands Tissue Antigens. 72: 321-334. PMID 18700879 DOI: 10.1111/J.1399-0039.2008.01106.X |
0.51 |
|
| 2008 |
Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3372-9. PMID 18519766 DOI: 10.1158/1078-0432.Ccr-07-4433 |
0.463 |
|
| 2008 |
Schwenkert M, Birkholz K, Schwemmlein M, Kellner C, Kügler M, Peipp M, Nettelbeck DM, Schuler-Thurner B, Schaft N, Dörrie J, Ferrone S, Kämpgen E, Fey GH. A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells. Melanoma Research. 18: 73-84. PMID 18337643 DOI: 10.1097/Cmr.0B013E3282F7C8F9 |
0.384 |
|
| 2008 |
Morandi F, Raffaghello L, Bianchi G, Meloni F, Salis A, Millo E, Ferrone S, Barnaba V, Pistoia V. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells (Dayton, Ohio). 26: 1275-87. PMID 18292209 DOI: 10.1634/Stemcells.2007-0878 |
0.468 |
|
| 2008 |
Belicha-Villanueva A, McEvoy S, Cycon K, Ferrone S, Gollnick SO, Bangia N. Differential contribution of TAP and tapasin to HLA class I antigen expression. Immunology. 124: 112-20. PMID 18194274 DOI: 10.1111/J.1365-2567.2007.02746.X |
0.457 |
|
| 2008 |
Wondimu A, Zhang T, Kieber-Emmons T, Gimotty P, Sproesser K, Somasundaram R, Ferrone S, Tsao CY, Herlyn D. Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunology, Immunotherapy : Cii. 57: 1079-89. PMID 18157673 DOI: 10.1007/S00262-007-0439-4 |
0.427 |
|
| 2008 |
Campoli M, Ferrone S. Anti-inflammatory biologic therapies and immune surveillance of melanoma Expert Review of Dermatology. 3: 129-131. DOI: 10.1586/17469872.3.2.129 |
0.305 |
|
| 2008 |
Andersson E, Johansson CC, Villabona L, Kanter L, Helgadottir H, Dalianis T, Bergfeldt K, Seliger B, Ferrone S, Kiessling R, Masucci GV. Survival rates in HLA-A2 positive patients, with stage III-IV serous adenocarcinomas of the ovary, correlates with increased expression of COX-2 and iNOS, loss of MHC Class I and II and defects of the antigen processing mechanisms at the tumour level Journal of Clinical Oncology. 26: 16544-16544. DOI: 10.1200/Jco.2008.26.15_Suppl.16544 |
0.403 |
|
| 2008 |
Seliger B, Ferrone S. HLA class I antigen abnormalities in tumors General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology. 123-144. DOI: 10.1007/978-1-4020-6087-8_6 |
0.343 |
|
| 2007 |
Signorino E, Brusa D, Granata R, Malavasi F, Ferrone S, Matera L. Contribution of dendritic cells' FcgammaRI and FcgammaRIII to cross-presentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies. Cancer Biology & Therapy. 6: 1932-7. PMID 18087220 DOI: 10.4161/Cbt.6.12.4973 |
0.531 |
|
| 2007 |
Ferrone S, Whiteside TL. Tumor Microenvironment and Immune Escape Surgical Oncology Clinics of North America. 16: 755-774. PMID 18022543 DOI: 10.1016/J.Soc.2007.08.004 |
0.426 |
|
| 2007 |
Pistoia V, Morandi F, Wang X, Ferrone S. Soluble HLA-G: Are they clinically relevant? Seminars in Cancer Biology. 17: 469-79. PMID 17825579 DOI: 10.1016/J.Semcancer.2007.07.004 |
0.358 |
|
| 2007 |
Tsuda N, Chang DZ, Mine T, Efferson C, García-Sastre A, Wang X, Ferrone S, Ioannides CG. Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells. Cancer Research. 67: 8378-87. PMID 17804754 DOI: 10.1158/0008-5472.Can-07-0327 |
0.419 |
|
| 2007 |
Ko E, Luo W, Peng L, Wang X, Ferrone S. Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity. Cancer Research. 67: 7875-84. PMID 17699794 DOI: 10.1158/0008-5472.Can-06-1744 |
0.433 |
|
| 2007 |
Connolly N, Riddler S, Stanson J, Gooding W, Rinaldo CR, Ferrone S, Whiteside TL. Levels of antigen processing machinery components in dendritic cells generated for vaccination of HIV-1+ subjects. Aids (London, England). 21: 1683-92. PMID 17690565 DOI: 10.1097/Qad.0B013E32825Eabbc |
0.343 |
|
| 2007 |
Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunology, Immunotherapy : Cii. 57: 197-206. PMID 17622526 DOI: 10.1007/S00262-007-0362-8 |
0.388 |
|
| 2007 |
Morandi F, Levreri I, Bocca P, Galleni B, Raffaghello L, Ferrone S, Prigione I, Pistoia V. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Research. 67: 6433-41. PMID 17616704 DOI: 10.1158/0008-5472.Can-06-4588 |
0.396 |
|
| 2007 |
Oflazoglu E, Elliott M, Takita H, Ferrone S, Henderson RA, Repasky EA. Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model. Journal of Translational Medicine. 5: 29. PMID 17592641 DOI: 10.1186/1479-5876-5-29 |
0.394 |
|
| 2007 |
Raffaghello L, Nozza P, Morandi F, Camoriano M, Wang X, Garrè ML, Cama A, Basso G, Ferrone S, Gambini C, Pistoia V. Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma. Cancer Research. 67: 5471-8. PMID 17545629 DOI: 10.1158/0008-5472.Can-06-4735 |
0.5 |
|
| 2007 |
Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, Weller M, Wiendl H. WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathologica. 114: 111-9. PMID 17541610 DOI: 10.1007/S00401-007-0231-8 |
0.489 |
|
| 2007 |
Theurillat J, Zürrer-Härdi U, Varga Z, Storz M, Probst-Hensch NM, Seifert B, Fehr MK, Fink D, Ferrone S, Pestalozzi B, Jungbluth AA, Chen Y, Jäger D, Knuth A, Moch H. NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunology, Immunotherapy. 56: 1723-1731. PMID 17410359 DOI: 10.1007/S00262-007-0316-1 |
0.396 |
|
| 2007 |
Vermeulen CF, Jordanova ES, ter Haar NT, Kolkman-Uljee SM, de Miranda NF, Ferrone S, Peters AA, Fleuren GJ. Expression and genetic analysis of transporter associated with antigen processing in cervical carcinoma. Gynecologic Oncology. 105: 593-9. PMID 17382375 DOI: 10.1016/J.Ygyno.2007.02.016 |
0.387 |
|
| 2007 |
Dierssen JW, de Miranda NF, Ferrone S, van Puijenbroek M, Cornelisse CJ, Fleuren GJ, van Wezel T, Morreau H. HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. Bmc Cancer. 7: 33. PMID 17316446 DOI: 10.1186/1471-2407-7-33 |
0.447 |
|
| 2007 |
Ogino T, Moriai S, Ishida Y, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, Ferrone S. Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. International Journal of Cancer. Journal International Du Cancer. 120: 2401-10. PMID 17315195 DOI: 10.1002/Ijc.22334 |
0.426 |
|
| 2007 |
Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3890-5. PMID 16818683 DOI: 10.1158/1078-0432.Ccr-05-2750 |
0.483 |
|
| 2007 |
Chang CC, Ferrone S. Immune selective pressure and HLA class I antigen defects in malignant lesions Cancer Immunology, Immunotherapy. 56: 227-236. PMID 16783578 DOI: 10.1007/S00262-006-0183-1 |
0.476 |
|
| 2006 |
Almeciga I, Wang ZC, Zúñiga J, Fernandez-Viña M, Clavijo O, Araujo H, Romero V, Henry J, Ferrone S, Yunis EJ. Allorecognition of an HLA-A*01 aberrant allele by an HLA identical family member carrying the HLA-A*0101 allele. Journal of Immunology (Baltimore, Md. : 1950). 177: 8643-9. PMID 17142764 DOI: 10.4049/Jimmunol.177.12.8643 |
0.394 |
|
| 2006 |
Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, ... ... Ferrone S, et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5503-10. PMID 17000686 DOI: 10.1158/1078-0432.Ccr-05-2670 |
0.313 |
|
| 2006 |
Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, Ferrone S. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Research. 66: 9281-9. PMID 16982773 DOI: 10.1158/0008-5472.Can-06-0488 |
0.468 |
|
| 2006 |
Chang CC, Ferrone S. NK cell activating ligands on human malignant cells: Molecular and functional defects and potential clinical relevance Seminars in Cancer Biology. 16: 383-392. PMID 16931041 DOI: 10.1016/J.Semcancer.2006.07.001 |
0.491 |
|
| 2006 |
Bangia N, Ferrone S. Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes? Immunological Investigations. 35: 485-503. PMID 16916763 DOI: 10.1080/08820130600808246 |
0.441 |
|
| 2006 |
Petti C, Molla A, Vegetti C, Ferrone S, Anichini A, Sensi M. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Research. 66: 6503-11. PMID 16818621 DOI: 10.1158/0008-5472.Can-05-4671 |
0.429 |
|
| 2006 |
Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E, Wang X, Ferrone S. Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Research. 66: 6405-11. PMID 16778219 DOI: 10.1158/0008-5472.Can-06-0854 |
0.473 |
|
| 2006 |
Luo W, Ko E, Hsu JC, Wang X, Ferrone S. Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. Journal of Immunology (Baltimore, Md. : 1950). 176: 6046-54. PMID 16670313 DOI: 10.4049/Jimmunol.176.10.6046 |
0.482 |
|
| 2006 |
Chang CC, Ogino T, Mullins DW, Oliver JL, Yamshchikov GV, Bandoh N, Slingluff CL, Ferrone S. Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. The Journal of Biological Chemistry. 281: 18763-73. PMID 16648140 DOI: 10.1074/Jbc.M511525200 |
0.434 |
|
| 2006 |
Slingluff CL, Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2342s-2345s. PMID 16609056 DOI: 10.1158/1078-0432.Ccr-05-2541 |
0.39 |
|
| 2006 |
López-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, Ferrone S, Ferris RL. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. Journal of Immunology (Baltimore, Md. : 1950). 176: 3402-9. PMID 16517708 DOI: 10.4049/Jimmunol.176.6.3402 |
0.431 |
|
| 2006 |
Peng L, Ko E, Luo W, Wang X, Shrikant PA, Ferrone S. CD4-dependent potentiation of a high molecular weight-melanoma-associated antigen-specific CTL response elicited in HLA-A2/Kb transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 176: 2307-15. PMID 16455987 DOI: 10.4049/Jimmunol.176.4.2307 |
0.454 |
|
| 2006 |
Reynolds SR, Vergilis IJ, Szarek M, Ferrone S, Bystryn JC. Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy? International Journal of Cancer. 119: 157-61. PMID 16450373 DOI: 10.1002/Ijc.21820 |
0.316 |
|
| 2006 |
Luo W, Wang X, Kageshita T, Wakasugi S, Karpf AR, Ferrone S. Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene. 25: 2873-84. PMID 16407841 DOI: 10.1038/Sj.Onc.1209319 |
0.373 |
|
| 2006 |
Albers A, Abe K, Hunt J, Wang J, Lopez-Albaitero A, Schaefer C, Gooding W, Whiteside TL, Ferrone S, DeLeo A, Ferris RL. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Research. 65: 11146-55. PMID 16322265 DOI: 10.1158/0008-5472.Can-05-0772 |
0.359 |
|
| 2006 |
Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Research. 65: 10139-44. PMID 16287995 DOI: 10.1158/0008-5472.Can-05-0097 |
0.492 |
|
| 2006 |
Claus JA, Brady MT, Lee J, Donohue KA, Sait SN, Ferrone S, Wetzler M. T-Cell activation by t(9;22) acute lymphoblastic leukemia-derived dendritic-like cells is associated with increased tapasin expression. Cancer Immunology, Immunotherapy : Cii. 55: 160-5. PMID 16010586 DOI: 10.1007/S00262-005-0012-Y |
0.464 |
|
| 2006 |
Vélez B, Grizzi F, Wenhan W, Pinkston J, Cunha ND, Cobos E, Kast WM, Ferrone S, Chiriva-Internati M. 190 TAPASIN AND HLA CLASS I DOWN-REGULATED IN PRIMARY HUMAN MULTIPLE MYELOMA: SUITABLE INDICATOR OF POOR PROGNOSIS. Journal of Investigative Medicine. 54: S290.2-S290. DOI: 10.2310/6650.2005.X0008.189 |
0.408 |
|
| 2006 |
Ferrone S, Campoli M. A fresh look at an old story: revisiting HLA class II antigen expression by melanoma cells Expert Review of Dermatology. 1: 805-823. DOI: 10.1586/17469872.1.6.805 |
0.463 |
|
| 2006 |
Drake AS, Michael BT, Wang XH, Sait SJ, Earp JC, Jusko WJ, Ferrone S, Wang ES, Wetzler M. The Effects of Anti-High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Monoclonal Antibodies (mAb) Against 11q23 Positive Acute Leukemia Cells. Blood. 108: 4550-4550. DOI: 10.1182/Blood.V108.11.4550.4550 |
0.413 |
|
| 2006 |
McCarthy J, Price M, Yang J, Iida J, Turley E, Ferrone S. Melanoma chondroitin sulfate proteoglycan promotes anchorage-independent growth of melanoma cells through activation of Erk1/2 Melanoma Research. 16: S95. DOI: 10.1097/00008390-200609001-00174 |
0.32 |
|
| 2006 |
Takata M, Matsumoto K, Kubo H, Saida T, Ferrone S, Kobayashi T. Hyperthermia for metastatic melanoma using monoclonal antibody-conjugated magneto-liposomes Melanoma Research. 16: S85-S86. DOI: 10.1097/00008390-200609001-00156 |
0.411 |
|
| 2006 |
Reynolds SR, Ferrone S, Bystryn JC. Response to: Circulating tumor cells and detection of melanoma-associated antigen HMW-MAA in the serum of melanoma patients [3] Journal of Investigative Dermatology. 126: 916. DOI: 10.1038/Sj.Jid.5700156 |
0.435 |
|
| 2005 |
Facoetti A, Nano R, Zelini P, Morbini P, Benericetti E, Ceroni M, Campoli M, Ferrone S. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8304-11. PMID 16322289 DOI: 10.1158/1078-0432.Ccr-04-2588 |
0.453 |
|
| 2005 |
Ferris RL, Hunt JL, Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: Molecular mechanisms and clinical significance Immunologic Research. 33: 113-133. PMID 16234579 DOI: 10.1385/Ir:33:2:113 |
0.485 |
|
| 2005 |
Chang CC, Hernandez-Guzman FG, Luo W, Wang X, Ferrone S, Ghosh D. Structural basis of antigen mimicry in a clinically relevant melanoma antigen system. The Journal of Biological Chemistry. 280: 41546-52. PMID 16227204 DOI: 10.1074/Jbc.M507562200 |
0.445 |
|
| 2005 |
Campoli M, Ferrone S, Zea AH, Rodriguez PC, Ochoa AC. Mechanisms of tumor evasion. Cancer Treatment and Research. 123: 61-88. PMID 16211866 DOI: 10.1007/0-387-27545-2_3 |
0.398 |
|
| 2005 |
Ramnath N, Tan D, Li Q, Hylander BL, Bogner P, Ryes L, Ferrone S. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunology, Immunotherapy : Cii. 55: 891-9. PMID 16187081 DOI: 10.1007/S00262-005-0085-7 |
0.407 |
|
| 2005 |
Vergilis IJ, Szarek M, Ferrone S, Reynolds SR. Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. The Journal of Investigative Dermatology. 125: 526-31. PMID 16117794 DOI: 10.1111/J.0022-202X.2005.23798.X |
0.331 |
|
| 2005 |
Tourkova IL, Shurin GV, Chatta GS, Perez L, Finke J, Whiteside TL, Ferrone S, Shurin MR. Restoration by IL-15 of MHC class I antigen-processing machinery in human dendritic cells inhibited by tumor-derived gangliosides. Journal of Immunology (Baltimore, Md. : 1950). 175: 3045-52. PMID 16116192 DOI: 10.4049/Jimmunol.175.5.3045 |
0.442 |
|
| 2005 |
Luo W, Hsu JC, Kieber-Emmons T, Wang X, Ferrone S. Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases. Cancer Chemotherapy and Biological Response Modifiers. 22: 769-87. PMID 16110640 DOI: 10.1016/S0921-4410(04)22036-1 |
0.437 |
|
| 2005 |
Bandoh N, Ogino T, Cho HS, Hur SY, Shen J, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens. 66: 185-94. PMID 16101829 DOI: 10.1111/J.1399-0039.2005.00462.X |
0.471 |
|
| 2005 |
Wang X, Ko EC, Peng L, Gillies SD, Ferrone S. Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2. Cancer Research. 65: 6976-83. PMID 16061683 DOI: 10.1158/0008-5472.Can-04-2328 |
0.432 |
|
| 2005 |
Sconocchia G, Lau M, Provenzano M, Rezvani K, Wongsena W, Fujiwara H, Hensel N, Melenhorst J, Li J, Ferrone S, Barrett AJ. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood. 106: 3666-72. PMID 16046526 DOI: 10.1182/Blood-2005-02-0479 |
0.365 |
|
| 2005 |
Yan WH, Lin AF, Chang CC, Ferrone S. Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2'-deoxycytidine. Cell Research. 15: 523-531. PMID 16045815 DOI: 10.1038/Sj.Cr.7290376 |
0.349 |
|
| 2005 |
Kloor M, Becker C, Benner A, Woerner SM, Gebert J, Ferrone S, von Knebel Doeberitz M. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Research. 65: 6418-24. PMID 16024646 DOI: 10.1158/0008-5472.Can-05-0044 |
0.406 |
|
| 2005 |
Kawano K, Ferrone S, Ioannides CG. Functional idiotopes: tumor antigen-directed expression of CD8+ T-cell epitopes nested in unique NH2-terminal VH sequence of antiidiotypic antibodies? Cancer Research. 65: 6001-4. PMID 16024597 DOI: 10.1158/0008-5472.Can-04-3400 |
0.465 |
|
| 2005 |
Seliger B, Ritz U, Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. International Journal of Cancer. 118: 129-38. PMID 16003759 DOI: 10.1002/Ijc.21312 |
0.478 |
|
| 2005 |
Raffaghello L, Prigione I, Airoldi I, Camoriano M, Morandi F, Bocca P, Gambini C, Ferrone S, Pistoia V. Mechanisms of immune evasion of human neuroblastoma. Cancer Letters. 228: 155-61. PMID 15923080 DOI: 10.1016/J.Canlet.2004.11.064 |
0.462 |
|
| 2005 |
Luo W, Hsu JC, Tsao CY, Ko E, Wang X, Ferrone S. Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. Journal of Immunology (Baltimore, Md. : 1950). 174: 7104-10. PMID 15905554 DOI: 10.4049/Jimmunol.174.11.7104 |
0.376 |
|
| 2005 |
Yamshchikov GV, Mullins DW, Chang CC, Ogino T, Thompson L, Presley J, Galavotti H, Aquila W, Deacon D, Ross W, Patterson JW, Engelhard VH, Ferrone S, Slingluff CL. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. Journal of Immunology (Baltimore, Md. : 1950). 174: 6863-71. PMID 15905528 DOI: 10.4049/Jimmunol.174.11.6863 |
0.45 |
|
| 2005 |
Raffaghello L, Prigione I, Bocca P, Morandi F, Camoriano M, Gambini C, Wang X, Ferrone S, Pistoia V. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene. 24: 4634-44. PMID 15897905 DOI: 10.1038/Sj.Onc.1208594 |
0.504 |
|
| 2005 |
Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, Shen J, Hur SY, Kageshita T, Ferrone S. A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. Journal of Immunological Methods. 299: 139-51. PMID 15896802 DOI: 10.1016/J.Jim.2005.02.006 |
0.444 |
|
| 2005 |
Kageshita T, Ishihara T, Campoli M, Ferrone S. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens. 65: 419-28. PMID 15853896 DOI: 10.1111/J.1399-0039.2005.00381.X |
0.424 |
|
| 2005 |
Bolesta E, Kowalczyk A, Wierzbicki A, Rotkiewicz P, Bambach B, Tsao CY, Horwacik I, Kolinski A, Rokita H, Brecher M, Wang X, Ferrone S, Kozbor D. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Research. 65: 3410-8. PMID 15833876 DOI: 10.1158/0008-5472.Can-04-2164 |
0.445 |
|
| 2005 |
Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2552-60. PMID 15814633 DOI: 10.1158/1078-0432.Ccr-04-2146 |
0.483 |
|
| 2005 |
Chang CC, Campoli M, Ferrone S. Classical and nonclassical HLA class I antigen and NK cell-activating ligand changes in malignant cells: Current challenges and future directions Advances in Cancer Research. 93: 189-234. PMID 15797448 DOI: 10.1016/S0065-230X(05)93006-6 |
0.457 |
|
| 2005 |
Campoli M, Chang CC, Oldford SA, Edgecombe AD, Drover S, Ferrone S. HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications. Breast Disease. 20: 105-25. PMID 15687712 DOI: 10.3233/Bd-2004-20112 |
0.518 |
|
| 2005 |
Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S. Immune selection of hot-spot β2-Microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy Journal of Immunology. 174: 1462-1471. PMID 15661905 DOI: 10.4049/Jimmunol.174.3.1462 |
0.454 |
|
| 2005 |
Chang CC, Campoli M, Luo W, Zhao W, Zaenker KS, Ferrone S. Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: potential role of nonimmunological mechanisms. Annals of the New York Academy of Sciences. 1028: 340-50. PMID 15650259 DOI: 10.1196/Annals.1322.040 |
0.466 |
|
| 2005 |
Prigione I, Corrias MV, Airoldi I, Raffaghello L, Morandi F, Bocca P, Cocco C, Ferrone S, Pistoia V. Immunogenicity of human neuroblastoma. Annals of the New York Academy of Sciences. 1028: 69-80. PMID 15650233 DOI: 10.1196/Annals.1322.008 |
0.502 |
|
| 2005 |
Wagner S, Hafner C, Allwardt D, Jasinska J, Ferrone S, Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H, Breiteneder H. Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. Journal of Immunology (Baltimore, Md. : 1950). 174: 976-82. PMID 15634921 DOI: 10.4049/Jimmunol.174.2.976 |
0.37 |
|
| 2005 |
Wang X, Campoli M, Ko E, Luo W, Ferrone S. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. Journal of Immunological Methods. 294: 23-35. PMID 15604013 DOI: 10.1016/J.Jim.2004.08.005 |
0.416 |
|
| 2005 |
Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Critical Reviews in Immunology. 24: 267-96. PMID 15588226 DOI: 10.1615/Critrevimmunol.V24.I4.40 |
0.439 |
|
| 2005 |
Hafner C, Breiteneder H, Ferrone S, Thallinger C, Wagner S, Schmidt WM, Jasinska J, Kundi M, Wolff K, Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H. Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. International Journal of Cancer. 114: 426-32. PMID 15578703 DOI: 10.1002/Ijc.20769 |
0.413 |
|
| 2005 |
Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S, Pistoia V. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia (New York, N.Y.). 6: 558-68. PMID 15548365 DOI: 10.1593/Neo.04316 |
0.444 |
|
| 2005 |
Chang CC, Campoli M, Ferrone S. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis? Current Opinion in Immunology. 16: 644-50. PMID 15342012 DOI: 10.1016/J.Coi.2004.07.015 |
0.508 |
|
| 2005 |
Padmanabhan S, Bansal H, Hylander B, Baer M, Ferrone S, Repasky E. Differential gene regulation of WT1 protein tumor antigen and the components of the antigen processing machinery by interferon-gamma signaling in myeloid leukemia Journal of Clinical Oncology. 23: 2587-2587. DOI: 10.1200/Jco.2005.23.16_Suppl.2587 |
0.42 |
|
| 2005 |
Wetzler M, Brady MT, Siat SN, Kakati S, Block AW, Wang X, Hunger SP, Carroll AJ, Ferrone S. Differential Antigenic Profile of High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Expressed by 11q23-Positive Acute Leukemia: An Immunotherapeutic Target. Blood. 106: 3261-3261. DOI: 10.1182/Blood.V106.11.3261.3261 |
0.349 |
|
| 2004 |
Ferrone S. Immunotherapy dispenses with tumor antigens Nature Biotechnology. 22: 1096-1098. PMID 15340476 DOI: 10.1038/Nbt0904-1096 |
0.456 |
|
| 2004 |
Murray JL, Gillogly M, Kawano K, Efferson CL, Lee JE, Ross M, Wang X, Ferrone S, Ioannides CG. Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. Cancer Research. 64: 5481-8. PMID 15289358 DOI: 10.1158/0008-5472.Can-04-0517 |
0.481 |
|
| 2004 |
Whiteside TL, Stanson J, Shurin MR, Ferrone S. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. Journal of Immunology (Baltimore, Md. : 1950). 173: 1526-34. PMID 15265880 DOI: 10.4049/Jimmunol.173.3.1526 |
0.411 |
|
| 2004 |
Yang J, Price MA, Neudauer CL, Wilson C, Ferrone S, Xia H, Iida J, Simpson MA, McCarthy JB. Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. The Journal of Cell Biology. 165: 881-91. PMID 15210734 DOI: 10.1083/Jcb.200403174 |
0.353 |
|
| 2004 |
Demanet C, Mulder A, Deneys V, Worsham MJ, Maes P, Claas FH, Ferrone S. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood. 103: 3122-30. PMID 15070694 DOI: 10.1182/Blood-2003-07-2500 |
0.47 |
|
| 2004 |
Campoli M, Ferrone S. T-cell-based immunotherapy of melanoma: What have we learned and how can we improve? Expert Review of Vaccines. 3: 171-187. PMID 15056043 DOI: 10.1586/14760584.3.2.171 |
0.426 |
|
| 2004 |
Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer F, Störkel S, Seliger B. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. International Journal of Cancer. 109: 265-73. PMID 14750179 DOI: 10.1002/Ijc.11681 |
0.332 |
|
| 2004 |
Chang CC, Campoli M, Ferrone S. HLA class I defects in malignant lesions: what have we learned? The Keio Journal of Medicine. 52: 220-9. PMID 14748474 DOI: 10.2302/Kjm.52.220 |
0.481 |
|
| 2004 |
Atkins D, Ferrone S, Schmahl GE, Störkel S, Seliger B. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? The Journal of Urology. 171: 885-9. PMID 14713847 DOI: 10.1097/01.Ju.0000094807.95420.Fe |
0.445 |
|
| 2004 |
Ko EC, Wang X, Ferrone S. Immunotherapy of malignant diseases. Challenges and strategies. International Archives of Allergy and Immunology. 132: 294-309. PMID 14707461 DOI: 10.1159/000074897 |
0.418 |
|
| 2004 |
Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens. 62: 385-93. PMID 14617045 DOI: 10.1034/J.1399-0039.2003.00114.X |
0.499 |
|
| 2004 |
Ogino T, Bandoh N, Hayashi T, Miyokawa N, Harabuchi Y, Ferrone S. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 4043-51. PMID 14519625 |
0.312 |
|
| 2004 |
Sabbatini P, Aghajanian C, Dupont J, Derosa F, Anderson S, McGuire W, Rodabaugh K, Ferrone S, Lele S, Odunsi K. Phase I trial of the anti-idiotypic monoclonal antibody (mAb) ACA-125 in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer Journal of Clinical Oncology. 22: 5018-5018. DOI: 10.1200/Jco.2004.22.90140.5018 |
0.361 |
|
| 2004 |
Claus JA, Brady MA, Lee J, Donohue KA, Ferrone S, Wetzler M. T Cell Activation by t(9;22) Acute Lymphoblastic Leukemia-Derived Dendritic-Like Cells Is Associated with Increased Expression of Antigen Processing Machinery Components. Blood. 104: 4301-4301. DOI: 10.1182/Blood.V104.11.4301.4301 |
0.482 |
|
| 2004 |
Sconocchia G, Lau M, Provenzano M, Rezvani K, Fujiwara H, Ferrone S, Barrett J. The Antileukemic Effect of NK and NK-T Cells Against Chronic Myelogenous Leukemia Is Dominated by Interactions between Activating Molecules and Their Ligands Which Overcome Inhibitory KIR-MHC Class I Interaction. Blood. 104: 2948-2948. DOI: 10.1182/Blood.V104.11.2948.2948 |
0.364 |
|
| 2003 |
Chang CC, Ferrone S. HLA-G in melanoma: Can the current controversies be solved? Seminars in Cancer Biology. 13: 361-369. PMID 14708716 DOI: 10.1016/S1044-579X(03)00027-0 |
0.399 |
|
| 2003 |
Chang CC, Murphy SP, Ferrone S. Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms. Human Immunology. 64: 1057-63. PMID 14602236 DOI: 10.1016/J.Humimm.2003.08.357 |
0.422 |
|
| 2003 |
Ogino T, Wang X, Ferrone S. Modified flow cytometry and cell-ELISA methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum. Journal of Immunological Methods. 278: 33-44. PMID 12957394 DOI: 10.1016/S0022-1759(03)00224-2 |
0.479 |
|
| 2003 |
Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. Journal of Immunology (Baltimore, Md. : 1950). 171: 1918-26. PMID 12902494 DOI: 10.4049/Jimmunol.171.4.1918 |
0.359 |
|
| 2003 |
Wang X, Liang B, Rebmann V, Lu J, Celis E, Kageshita T, Grosse-Wilde H, Ferrone S. Specificity and functional characteristics of anti-HLA-A mAbs LGIII-147.4.1 and LGIII-220.6.2. Tissue Antigens. 62: 139-48. PMID 12889994 DOI: 10.1034/J.1399-0039.2003.00087.X |
0.594 |
|
| 2003 |
Dissemond J, Goette P, Moers J, Lindeke A, Goos M, Ferrone S, Wagner SN. Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: association with lack of spontaneous regression. Melanoma Research. 13: 371-377. PMID 12883363 DOI: 10.1097/00008390-200308000-00006 |
0.419 |
|
| 2003 |
Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends in Immunology. 24: 335-42. PMID 12810110 DOI: 10.1016/S1471-4906(03)00116-9 |
0.377 |
|
| 2003 |
Dissemond J, Götte P, Mörs J, Lindeke A, Goos M, Ferrone S, Wagner SN. Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression. Melanoma Research. 13: 253-258. PMID 12777979 DOI: 10.1097/00008390-200306000-00005 |
0.366 |
|
| 2003 |
Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, Störkel S. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 1721-7. PMID 12738726 |
0.302 |
|
| 2003 |
Weinman EC, Roche PC, Kasperbauer JL, Cha SS, Sargent DJ, Cheville J, Murphy LM, Chen L, Wettstein PJ, Gostout B, Ferrone S, Strome SE. Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma Cancer. 97: 2203-2211. PMID 12712472 DOI: 10.1002/cncr.11311 |
0.416 |
|
| 2003 |
Wetzler M, McElwain BK, Stewart CC, Blumenson L, Mortazavi A, Ford LA, Slack JL, Barcos M, Ferrone S, Baer MR. HLA-DR antigen-negative acute myeloid leukemia. Leukemia. 17: 707-15. PMID 12682628 DOI: 10.1038/Sj.Leu.2402865 |
0.436 |
|
| 2003 |
Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. European Journal of Immunology. 33: 125-34. PMID 12594841 DOI: 10.1002/Immu.200390015 |
0.418 |
|
| 2003 |
Yang T, McNally BA, Ferrone S, Liu Y, Zheng P. A single-nucleotide deletion leads to rapid degradation of TAP-1 mRNA in a melanoma cell line. The Journal of Biological Chemistry. 278: 15291-6. PMID 12582163 DOI: 10.1074/Jbc.M300954200 |
0.392 |
|
| 2003 |
Seliger B, Abken H, Ferrone S. HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends in Immunology. 24: 82-7. PMID 12547505 DOI: 10.1016/S1471-4906(02)00039-X |
0.455 |
|
| 2003 |
Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine. A40-5. PMID 12477427 DOI: 10.1016/S0264-410X(02)00386-9 |
0.457 |
|
| 2002 |
Ferrone S. Changes in serum ganglioside and antibody levels in soft tissue sarcoma: Are they the cause or the effect of tumor progression? Cancer Journal. 8: 369-370. PMID 12416893 DOI: 10.1097/00130404-200209000-00006 |
0.342 |
|
| 2002 |
Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Research. 62: 6178-86. PMID 12414645 |
0.346 |
|
| 2002 |
Rothenfusser S, Buchwald A, Kock S, Ferrone S, Fisch P. Missing HLA class I expression on Daudi cells unveils cytotoxic and proliferative responses of human gammadelta T lymphocytes. Cellular Immunology. 215: 32-44. PMID 12142034 DOI: 10.1016/S0008-8749(02)00001-1 |
0.464 |
|
| 2002 |
Wang ZC, Smith AG, Yunis EJ, Selvakumar A, Ferrone S, McKinney S, Lee JH, Fernandez-Vina M, Hansen JA. Molecular characterization of the HLA-Cw*0409N allele. Human Immunology. 63: 295-300. PMID 12039411 DOI: 10.1016/S0198-8859(02)00376-2 |
0.435 |
|
| 2002 |
Noronha EJ, Wang X, Ferrone S. Isolation of human tumor-associated cell surface antigen-binding scFvs Methods in Molecular Biology (Clifton, N.J.). 178: 227-233. PMID 11968492 DOI: 10.1385/1-59259-240-6:227 |
0.404 |
|
| 2002 |
Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Seminars in Cancer Biology. 12: 3-13. PMID 11926409 DOI: 10.1006/Scbi.2001.0404 |
0.483 |
|
| 2001 |
Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer. 92: 369-76. PMID 11466692 DOI: 10.1002/1097-0142(20010715)92:2<369::AID-CNCR1332>3.0.CO;2-U |
0.332 |
|
| 2001 |
Wetzler M, Baer MR, Stewart SJ, Donohue K, Ford L, Stewart CC, Repasky EA, Ferrone S. HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Leukemia. 15: 128-33. PMID 11243380 DOI: 10.1038/Sj.Leu.2401982 |
0.518 |
|
| 2001 |
Kamarashev J, Ferrone S, Seifert B, Böni R, Nestle FO, Burg G, Dummer R. TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. International Journal of Cancer. 95: 23-8. PMID 11241306 DOI: 10.1002/1097-0215(20010120)95:1<23::Aid-Ijc1004>3.0.Co;2-4 |
0.425 |
|
| 2001 |
Ferrone S, Wang X. Active specific immunotherapy of malignant melanoma and peptide mimics of the human high-molecular-weight melanoma-associated antigen Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 158: 231-235. PMID 11092050 DOI: 10.1007/978-3-642-59537-0_23 |
0.493 |
|
| 2000 |
Kiessling R, Pawelec G, Welsh RM, Barry JD, Ferrone S. Have tumor cells learnt from microorganisms how to fool the immune system? Molecular Medicine Today. 6: 344-346. PMID 11202973 DOI: 10.1016/S1357-4310(00)01778-0 |
0.37 |
|
| 2000 |
Paul P, Rouas-Freiss N, Moreau P, Cabestre FA, Menier C, Khalil-Daher I, Pangault C, Onno M, Fauchet R, Martinez-Laso J, Morales P, Villena AA, Giacomini P, Natali PG, Frumento G, ... ... Ferrone S, et al. HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Human Immunology. 61: 1177-95. PMID 11137224 DOI: 10.1016/S0198-8859(00)00154-3 |
0.407 |
|
| 2000 |
Desai SA, Wang X, Noronha EJ, Zhou Q, Rebmann V, Grosse-Wilde H, Moy FJ, Powers R, Ferrone S. Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on beta 2-microglobulin-associated and beta 2-microglobulin-free HLA class I heavy chains. Journal of Immunology (Baltimore, Md. : 1950). 165: 3275-83. PMID 10975844 DOI: 10.4049/Jimmunol.165.6.3275 |
0.39 |
|
| 2000 |
Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunology Today. 21: 455-64. PMID 10953098 DOI: 10.1016/S0167-5699(00)01692-3 |
0.443 |
|
| 2000 |
Moy FJ, Desai SA, Wang X, Noronha EJ, Zhou Q, Ferrone S, Powers R. Analysis by NMR spectroscopy of the structural homology between the linear and the cyclic peptide recognized by anti-human leukocyte antigen class I monoclonal antibody TP25.99*. The Journal of Biological Chemistry. 275: 24679-85. PMID 10825172 DOI: 10.1074/Jbc.M003647200 |
0.356 |
|
| 2000 |
Ferrone S, Finerty JF, Jaffee EM, Nabel GJ. How much longer will tumour cells fool the immune system? Immunology Today. 21: 70-2. PMID 10712001 DOI: 10.1016/S0167-5699(99)01569-8 |
0.34 |
|
| 2000 |
Puppo F, Contini P, Ghio M, Brenci S, Scudeletti M, Filaci G, Ferrone S, Indiveri F. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8+ Fas (CD95)+ T lymphocytes International Immunology. 12: 195-203. PMID 10653855 DOI: 10.1093/Intimm/12.2.195 |
0.387 |
|
| 2000 |
Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Advances in Immunology. 74: 181-273. PMID 10605607 DOI: 10.1016/S0065-2776(08)60911-6 |
0.433 |
|
| 2000 |
Perosa F, Prete M, Luccarelli G, Favoino B, Ferrone S, Dammacco F. Serum levels of beta-2-microglobulin-free heavy chain of HLA class I antigen in healthy individuals: relationship to their class I allotype. Human Immunology. 60: 1058-66. PMID 10600003 DOI: 10.1016/S0198-8859(99)00081-6 |
0.36 |
|
| 2000 |
Finke J, Ferrone S, Frey A, Mufson A, Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunology Today. 20: 158-60. PMID 10203710 DOI: 10.1016/S0167-5699(98)01435-2 |
0.36 |
|
| 2000 |
Völk H, Charlemagne J, Tournefier A, Ferrone S, Jost R, Parisot R, Kaufman J. Wide tissue distribution of axolotl class II molecules occurs independently of thyroxin. Immunogenetics. 47: 339-49. PMID 9510551 DOI: 10.1007/S002510050368 |
0.35 |
|
| 1999 |
Perosa F, Luccarelli G, Prete M, Ferrone S, Dammacco F. Increased serum levels of beta2m-free HLA class I heavy chain in multiple myeloma. British Journal of Haematology. 106: 987-94. PMID 10520002 DOI: 10.1046/J.1365-2141.1999.01635.X |
0.301 |
|
| 1999 |
Willers J, Lucchese A, Kanduc D, Ferrone S. Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside. Peptides. 20: 1021-6. PMID 10499418 DOI: 10.1016/S0196-9781(99)00095-9 |
0.331 |
|
| 1999 |
Wang Z, Marincola FM, Rivoltini L, Parmiani G, Ferrone S. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. The Journal of Experimental Medicine. 190: 205-15. PMID 10432284 DOI: 10.1084/Jem.190.2.205 |
0.421 |
|
| 1999 |
Reinhold U, Liu L, Lüdtke-Handjery HC, Heuser C, Hombach A, Wang X, Tilgen W, Ferrone S, Abken H. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor. The Journal of Investigative Dermatology. 112: 744-50. PMID 10233766 DOI: 10.1046/J.1523-1747.1999.00586.X |
0.466 |
|
| 1999 |
Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Molecular Medicine Today. 5: 178-86. PMID 10203751 DOI: 10.1016/S1357-4310(99)01451-3 |
0.481 |
|
| 1999 |
Puppo F, Bignardi D, Contini P, Hamby CV, Brenci S, Lanza L, Ghio M, Scudeletti M, Indiveri F, Ferrone S. β2-μ-free HLA class I heavy chain levels in sera of healthy individuals. Lack of association with β2-μ-associated HLA class I heavy chain levels and HLA phenotype Tissue Antigens. 53: 253-262. PMID 10203018 DOI: 10.1034/J.1399-0039.1999.530305.X |
0.339 |
|
| 1999 |
Rebmann V, Pfeiffer K, Pässler M, Ferrone S, Maier S, Weiss E, Grosse-Wilde H. Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens. 53: 14-22. PMID 10082427 DOI: 10.1034/J.1399-0039.1999.530102.X |
0.359 |
|
| 1999 |
Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. The American Journal of Pathology. 154: 745-54. PMID 10079252 DOI: 10.1016/S0002-9440(10)65321-7 |
0.44 |
|
| 1999 |
Cormier JN, Panelli MC, Hackett JA, Bettinotti MP, Mixon A, Wunderlich J, Parker LL, Restifo NP, Ferrone S, Marincola FM. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. International Journal of Cancer. Journal International Du Cancer. 80: 781-90. PMID 10048982 DOI: 10.1002/(Sici)1097-0215(19990301)80:5<781::Aid-Ijc24>3.0.Co;2-A |
0.469 |
|
| 1999 |
Perosa F, Luccarelli G, Neri M, De Pinto V, Ferrone S, Dammacco F. Evaluation of biotinylated cells as a source of antigens for characterization of their molecular profile. International Journal of Clinical & Laboratory Research. 28: 246-51. PMID 9879499 DOI: 10.1007/S005990050053 |
0.481 |
|
| 1999 |
Zhou Q, Desai SA, Wang X, Noronha EJ, Neri M, Ferrone S. Identification of monoclonal antibody defined epitopes on human leukocyte antigens utilizing phage display peptide libraries Letters in Peptide Science. 6: 77-86. DOI: 10.1007/Bf02443621 |
0.443 |
|
| 1998 |
Hamby CV, Chinol M, Palestro CJ, Manzo C, Ferrone S. Improved tumor targeting of rhenium-186-labeled anti-human high-M.W. Melanoma-associated antigen monoclonal antibody 763.74 following purification with anti-idiotypic monoclonal antibody MK2-23 International Journal of Cancer. 78: 486-490. PMID 9797138 DOI: 10.1002/(Sici)1097-0215(19981109)78:4<486::Aid-Ijc15>3.0.Co;2-4 |
0.433 |
|
| 1998 |
Fayen J, Huang JH, Ferrone S, Tykocinski ML. Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events. International Immunology. 10: 1347-58. PMID 9786434 DOI: 10.1093/Intimm/10.9.1347 |
0.467 |
|
| 1998 |
Wang Z, Arienti F, Parmiani G, Ferrone S. Induction and functional characterization of beta2-microglobulin (beta2-mu)-free HLA class I heavy chains expressed by beta2-mu-deficient human FO-1 melanoma cells. European Journal of Immunology. 28: 2817-26. PMID 9754569 DOI: 10.1002/(Sici)1521-4141(199809)28:09<2817::Aid-Immu2817>3.0.Co;2-M |
0.387 |
|
| 1998 |
Bresciani A, Pirozzi G, Spera M, Lombardi ML, Ambrosone L, Migliaresi S, Ferrone S, Manzo C. Increased level of serum HLA class I antigens in patients with systemic lupus in patients with systemic lupus erythematosus. Correlation with disease activity. Tissue Antigens. 52: 44-50. PMID 9714473 DOI: 10.1111/J.1399-0039.1998.Tb03022.X |
0.398 |
|
| 1998 |
Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. The Journal of Clinical Investigation. 101: 2720-9. PMID 9637706 DOI: 10.1172/Jci498 |
0.435 |
|
| 1998 |
Chatterjee-Kishore M, Kishore R, Hicklin DJ, Marincola FM, Ferrone S. Different requirements for signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression. The Journal of Biological Chemistry. 273: 16177-83. PMID 9632673 DOI: 10.1074/Jbc.273.26.16177 |
0.33 |
|
| 1998 |
Kishore R, Hicklin DJ, Dellaratta DV, Golde U, Kageshita T, Seliger B, Ferrone S. Development and characterization of mouse anti-human LMP2, LMP7, TAP1 and TAP2 monoclonal antibodies. Tissue Antigens. 51: 129-40. PMID 9510369 DOI: 10.1111/J.1399-0039.1998.Tb02958.X |
0.486 |
|
| 1998 |
Abken H, Hombach A, Reinhold U, Ferrone S. Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? Immunology Today. 19: 2-5. PMID 9465480 DOI: 10.1016/S0167-5699(97)01191-2 |
0.48 |
|
| 1998 |
Fisch P, Meuer E, Pende D, Rothenfusser S, Viale O, Kock S, Ferrone S, Fradelizi D, Klein G, Moretta L, Rammensee HG, Boon T, Coulie P, van der Bruggen P. Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vgamma9/Vdelta2 T cells in tumor immunity. European Journal of Immunology. 27: 3368-79. PMID 9464825 DOI: 10.1002/Eji.1830271236 |
0.446 |
|
| 1998 |
Dellaratta DV, Hicklin DJ, Kishore R, Kageshita T, Ferrone S. Characterization of rabbit antisera elicited with human LMP2- and LMP7-specific peptides and recombinant proteins. Tissue Antigens. 50: 567-75. PMID 9458109 DOI: 10.1111/J.1399-0039.1997.Tb02914.X |
0.419 |
|
| 1998 |
Mutz M, Hawthorne T, Ferrone S, Pluschke G. Titration calorimetry study of an anti-idiotypic antibody cascade in a human melanoma-associated antigen system. Molecular Immunology. 34: 695-707. PMID 9430197 DOI: 10.1016/S0161-5890(97)00095-3 |
0.373 |
|
| 1998 |
Reinhold U, Liu L, Heuser C, Hombach A, Ferrone S, Abken H. Anti-idiotypic monoclonal antibodies enhance the in-vitro cytotoxicity of CTL targeted to melanoma cells by Grafted chimeric receptors Journal of Dermatological Science. 16: S161. DOI: 10.1016/S0923-1811(98)83963-7 |
0.423 |
|
| 1998 |
Ugurel S, Seiter S, Rappl G, Tilgen W, Ferrone S, Reinhold U. Interferons upregulate abnormal TAP and LMP expression in melanoma cells lines Journal of Dermatological Science. 16: S160. DOI: 10.1016/S0923-1811(98)83956-X |
0.341 |
|
| 1997 |
Hicklin DJ, Dellaratta DV, Kishore R, Liang B, Kageshita T, Ferrone S. Beta2-microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance. Melanoma Research. 7: S67-74. PMID 9578419 DOI: 10.1097/00008390-199708001-00011 |
0.665 |
|
| 1997 |
Zhu X, Bavari S, Ulrich R, Sadegh-Nasseri S, Ferrone S, McHugh L, Mage M. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of α chain, β chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens European Journal of Immunology. 27: 1933-1941. PMID 9295029 DOI: 10.1002/Eji.1830270817 |
0.395 |
|
| 1997 |
Turco MC, Romano MF, Lamberti A, Petrella A, Bisogni R, Sun SC, Ferrone S, Bonelli P, Cerra M, Venuta S. Induction of nuclear factor kappa B/Rel nuclear activity in human peripheral blood T lymphocytes by anti-HLA class I monoclonal antibodies. Tissue Antigens. 50: 1-7. PMID 9243748 DOI: 10.1111/J.1399-0039.1997.Tb02826.X |
0.428 |
|
| 1997 |
Puppo F, Indiveri F, Scudeletti M, Ferrone S. Soluble HLA antigens: New roles and uses Immunology Today. 18: 154-155. PMID 9136450 DOI: 10.1016/S0167-5699(97)84660-9 |
0.437 |
|
| 1997 |
Natali PG, Hamby CV, Felding-Habermann B, Liang B, Nicotra MR, Di Filippo F, Giannarelli D, Temponi M, Ferrone S. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Research. 57: 1554-60. PMID 9108459 |
0.507 |
|
| 1997 |
Hamby CV, Chinol M, Manzo G, Ferrone S. Purification by affinity chromatography with anti-idiotypic monoclonal antibodies of immunoreactive monoclonal antibodies following labeling with 188Re Hybridoma. 16: 27-31. PMID 9085125 DOI: 10.1089/Hyb.1997.16.27 |
0.415 |
|
| 1997 |
Wang Z, Margulies L, Hicklin DJ, Ferrone S. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression. Tissue Antigens. 47: 382-90. PMID 8795138 DOI: 10.1111/J.1399-0039.1996.Tb02573.X |
0.486 |
|
| 1997 |
Kageshita T, Hirai S, Ferrone S, Ono T. High frequency loss of HLA class I allospecificities in primary and metastatic melanoma lesions Melanoma Research. 7: S140. DOI: 10.1097/00008390-199706001-00486 |
0.318 |
|
| 1997 |
Ferrone S, Desai S, Wang X, Zhang D, Noronha E, Kymisses A. Active specific immunotherapy with mouse anti-idiotypic (anti-id) mAb MK2???23 Melanoma Research. 7: S52. DOI: 10.1097/00008390-199706001-00180 |
0.352 |
|
| 1997 |
Seliger B, Maeurer MJ, Ferrone S. TAP off — tumors on Immunology Today. 18: 292-299. DOI: 10.1016/S0167-5699(97)80026-6 |
0.457 |
|
| 1996 |
Merimsky O, Shoenfeld Y, Baharav E, Altomonte M, Chaitchik S, Maio M, Ferrone S, Fishman P. Melanoma-associated hypopigmentation: where are the antibodies? American Journal of Clinical Oncology. 19: 613-8. PMID 8931683 DOI: 10.1097/00000421-199612000-00017 |
0.418 |
|
| 1996 |
Boccaletti V, Temponi M, Wang Z, Manganoni AM, Marcelli M, Maio M, Ferrone S, Panfilis GD. The vitronectin receptor alpha-V beta-3, contrary to ICAM-1, is not modulated by interferon-gamma and tumour necrosis factor-alpha on melanoma cell lines. Acta Dermato-Venereologica. 76: 269-273. PMID 8869681 DOI: 10.2340/0001555576269273 |
0.321 |
|
| 1996 |
Hicklin DJ, Kageshita T, Ferrone S. Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing Tissue Antigens. 48: 38-46. PMID 8864173 DOI: 10.1111/J.1399-0039.1996.Tb02603.X |
0.509 |
|
| 1996 |
Ferrone S. Anti-idiotypic monoclonal antibodies as therapeutic vaccines Melanoma Research. 6: 179. PMID 8791277 DOI: 10.1097/00008390-199604000-00014 |
0.344 |
|
| 1996 |
Ban N, Day J, Wang X, Ferrone S, McPherson A. Crystal structure of an anti-anti-idiotype shows it to be self-complementary. Journal of Molecular Biology. 255: 617-27. PMID 8568901 DOI: 10.1006/Jmbi.1996.0051 |
0.364 |
|
| 1996 |
Baharav E, Merimsky O, Altomonte M, Shoenfeld Y, Pavlovic M, Maio M, Ferrone S, Fishman P. Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high-molecular-weight melanoma-associated antigen. Melanoma Research. 5: 337-43. PMID 8541724 DOI: 10.1097/00008390-199510000-00006 |
0.422 |
|
| 1996 |
Bresciani A, Pirozzi G, Lombardi M, Mercuro O, Gallo A, Ferrone S, Manzo C. Presence of soluble forms of HLA class I and ICAM-1 in urine of patients with bladder tumor Human Immunology. 47: 150. DOI: 10.1016/0198-8859(96)85513-3 |
0.374 |
|
| 1996 |
Hackett J, Simonis T, Mixon A, Wunderlich J, Ferrone S, Marincola F. Variability in HLA-A2 antigen expression by melanoma cell lines. Functional implications Human Immunology. 47: 24. DOI: 10.1016/0198-8859(96)84805-1 |
0.414 |
|
| 1996 |
Wang Z, Marincola FM, Ferrone S. Molecular analysis of the selective loss of HLA-A2 antigen expression by melanoma cells 624 MEL28 Human Immunology. 47: 24. DOI: 10.1016/0198-8859(96)84803-8 |
0.418 |
|
| 1996 |
Hicklin DJ, Kageshita T, Dellaratta DV, Ferrone S. Loss of LMP and TAP expression in human melanoma cells Human Immunology. 47: 22. DOI: 10.1016/0198-8859(96)84794-X |
0.366 |
|
| 1995 |
Castagnoli C, Stella M, Magliacani G, Ferrone S, Richiardi PM. Similar ectopic expression of ICAM-1 and HLA class II molecules in hypertrophic scars following thermal injury. Burns : Journal of the International Society For Burn Injuries. 20: 430-3. PMID 7999272 DOI: 10.1016/0305-4179(94)90036-1 |
0.397 |
|
| 1995 |
Kageshita T, Hirai S, Ono T, Ferrone S. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic MAb MK2-23. Immunohistochemical analysis of the reactivity of anti-anti-idiotypic MAb with surgically removed melanoma lesions International Journal of Cancer. 60: 334-340. PMID 7829240 DOI: 10.1002/Ijc.2910600310 |
0.427 |
|
| 1995 |
Puppo F, Scudeletti M, Indiveri F, Ferrone S. Serum HLA class I antigens: markers and modulators of an immune response? Immunology Today. 16: 124-127. PMID 7718084 DOI: 10.1016/0167-5699(95)80127-8 |
0.436 |
|
| 1995 |
Iwasaki Y, Takabatake H, Monestier M, Ferrone S. Idiotypic diversity and variable region gene usage by mouse anti-HLA-DQ3 mAb Immunogenetics. 42: 90-100. PMID 7607710 DOI: 10.1007/Bf00178583 |
0.435 |
|
| 1995 |
Mittelman A, Wang X, Matsumoto K, Ferrone S. Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Hybridoma. 14: 175-81. PMID 7590776 DOI: 10.1089/Hyb.1995.14.175 |
0.425 |
|
| 1995 |
Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinial relevance Immunology Today. 16: 487-494. PMID 7576053 DOI: 10.1016/0167-5699(95)80033-6 |
0.47 |
|
| 1995 |
Matsumoto K, Saida T, Hirai S, Ferrone S. 151 Immunogenicity of chimeric (Fc portion is human) anti-idiotypic monoclonal antibody MK2-23, an internal image of human high molecular weight-melanoma associated antigen Journal of Dermatological Science. 10: 88. DOI: 10.1016/0923-1811(95)93866-Y |
0.414 |
|
| 1994 |
Kageshita T, Kimura T, Yoshii A, Hirai S, Ono T, Ferrone S. Antigenic profile of mucosal melanoma lesions International Journal of Cancer. 56: 370-374. PMID 8314324 DOI: 10.1002/Ijc.2910560313 |
0.389 |
|
| 1994 |
Ferrone S. Melanoma, immune surveillance, and immunotherapy Journal of Clinical Investigation. 93: 1351-1352. PMID 8163637 DOI: 10.1172/Jci117108 |
0.32 |
|
| 1994 |
Takamiya Y, Schönbach C, Nokihara K, Yamaguchi M, Ferrone S, Kano K, Egawa K, Takiguchi M. HLA-B*3501-peptide interactions: role of anchor residues of peptides in their binding to HLA-B*3501 molecules. International Immunology. 6: 255-61. PMID 8155602 DOI: 10.1093/Intimm/6.2.255 |
0.319 |
|
| 1994 |
Gattoni-Celli S, Byers RH, Calorini L, Ferrone S. Organ-specific metastases in melanoma: experimental animal models. Pigment Cell Research. 6: 381-4. PMID 8146087 DOI: 10.1111/J.1600-0749.1993.Tb00619.X |
0.363 |
|
| 1994 |
Di Rosa F, D'Oro U, Ruggiero G, Racioppi L, Acquaviva A, Ferrone S, Fontana S, Zappacosta S. HLA class II molecules transduce accessory signals affecting the CD3 but not the interleukin-2 activation pathway in T blasts. Human Immunology. 38: 251-60. PMID 8138420 DOI: 10.1016/0198-8859(93)90552-C |
0.352 |
|
| 1994 |
Puppo F, Brenci S, Lanza L, Bosco O, Imro MA, Scudeletti M, Indiveri F, Ferrone S. Increased level of serum HLA class I antigens in HIV infection correlation with disease progression Human Immunology. 40: 259-266. PMID 8002375 DOI: 10.1016/0198-8859(94)90025-6 |
0.357 |
|
| 1994 |
Iwasaki Y, Takahatake H, Shinji T, Monestier M, Ferrone S. Structural profile of idiotype, anti-idiotype and anti-anti-idiotype monoclonal antibodies in the HLA-DQ3 antigenic system European Journal of Immunology. 24: 2874-2881. PMID 7957578 DOI: 10.1002/Eji.1830241144 |
0.425 |
|
| 1994 |
Shoenfeld Y, Amital H, Ferrone S, Kennedy RC. Anti-idiotypes and their application under autoimmune, neoplastic, and infectious conditions. International Archives of Allergy and Immunology. 105: 211-23. PMID 7920023 DOI: 10.1159/000236760 |
0.389 |
|
| 1994 |
Pouletty P, Ferrone S, Amesland F, Cohen N, Westhoff U, Charron D, Shimizu RM, Grosse-Wilde H. Summary report from the first international workshop on soluble HLA antigens. Paris, August 1992. Tissue Antigens. 42: 45-54. PMID 7504328 DOI: 10.1111/J.1399-0039.1993.Tb02166.X |
0.479 |
|
| 1994 |
Boccaletti V, Wang Z, Temponi M, Manganoni A, Ferrone S, Panfilis GD. ICAM-1 expression is not regulated by IL-1 in human melanoma cell lines Journal of Investigative Dermatology. 103: 450. DOI: 10.5555/Uri:Pii:0022202X94925003 |
0.311 |
|
| 1993 |
Armandola EA, Mariani SM, Ferrone S. Serological and molecular characterization of mouse anti-idiotypic monoclonal antibodies elicited with the syngeneic Anti-HLA-A2,28 monoclonal antibody CR11-351 Molecular Immunology. 30: 287-300. PMID 8433707 DOI: 10.1016/0161-5890(93)90057-I |
0.419 |
|
| 1993 |
Wang Z, Cao Y, Albino AP, Zeff RA, Houghton A, Ferrone S. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. The Journal of Clinical Investigation. 91: 684-92. PMID 8432869 DOI: 10.1172/Jci116249 |
0.413 |
|
| 1993 |
Fishman P, Azizi E, Shoenfeld Y, Sredni B, Yecheskel G, Ferrone S, Zigelman R, Chaitchik S, Floro S, Djaldetti M. Vitiligo autoantibodies are effective against melanoma Cancer. 72: 2365-2369. PMID 8402450 DOI: 10.1002/1097-0142(19931015)72:8<2365::Aid-Cncr2820720812>3.0.Co;2-G |
0.312 |
|
| 1993 |
Chen ZJ, Ferrone S. Comparison of the binding parameters to melanoma cells of antihuman high molecular weight-melanoma associated antigen (HMW-MAA) monoclonal antibodies (mAb) and syngeneic Anti-Anti-idiotypic (Anti-Anti-id) mAb Annals of the New York Academy of Sciences. 690: 398-401. PMID 8368768 DOI: 10.1111/J.1749-6632.1993.Tb44043.X |
0.413 |
|
| 1993 |
Ferrone S. Human tumor-associated antigen mimicry by anti-idiotypic antibodies. Immunogenicity and clinical trials in patients with solid tumors Annals of the New York Academy of Sciences. 690: 214-224. PMID 8368740 DOI: 10.1111/J.1749-6632.1993.Tb44010.X |
0.418 |
|
| 1993 |
Ferrone S, Chen ZJ, Liu CC, Hirai S, Kageshita T, Mittelman A. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibodies MK2-23. Experimental studies and clinical trials in patients with malignant melanoma. Pharmacology & Therapeutics. 57: 259-90. PMID 8361995 DOI: 10.1016/0163-7258(93)90058-L |
0.453 |
|
| 1993 |
Ferrone S. Anti-idiotypes in Melanoma Hybridoma. 12: 509-514. PMID 8300123 DOI: 10.1089/Hyb.1993.12.509 |
0.339 |
|
| 1993 |
Pouletty P, Chang C, Kalil J, Atwood E, Ferrone S, Shimizu B, Howson W, Mazaheri R, Del Villano B, Grumet C. Typing of serum-soluble HLA-B27 antigen by ELISA Tissue Antigens. 42: 14-19. PMID 8248889 DOI: 10.1111/j.1399-0039.1993.tb02160.x |
0.337 |
|
| 1993 |
Ferrone S, Kageshita T, Hirai S. Active specific immunotherapy of malignant melanoma with anti-idiotypic monoclonal antibodies Journal of Dermatology. 20: 533-539. PMID 8227707 DOI: 10.1111/J.1346-8138.1993.Tb01334.X |
0.436 |
|
| 1993 |
Wang Z, Tatake RJ, Yang SY, Hu XZ, Zeff RA, Ferrone S. Differential Effect of Human and Mouse β2-Microglobulin on the Induction and the Antigenic Profile of Endogenous HLA-A and -B Antigens Synthesized by β2-Microglobulin Gene-null FO-1 Melanoma Cells Cancer Research. 53: 4303-4309. PMID 7689931 |
0.344 |
|
| 1993 |
Yang H, Chen ZJ, Kageshita T, Yamada M, Ferrone S. Idiotypic cascade in the human high molecular weight melanoma-associated antigen system: fine specificity and idiotypic profile of anti-anti-idiotypic monoclonal antibodies. European Journal of Immunology. 23: 1671-7. PMID 7686858 DOI: 10.1002/Eji.1830230741 |
0.396 |
|
| 1993 |
Mariani SM, Armandola EA, Ferrone S. Preferential selection of a subset of Anti-HLA-DR monoclonal antibodies by a syngeneic anti-idiotypic monoclonal antibody Transplantation. 55: 1176-1181. PMID 7684538 DOI: 10.1097/00007890-199305000-00044 |
0.455 |
|
| 1993 |
Kageshita T, Kimura T, Yoshii A, Ono T, Ferrone S. Analysis of the antigenic profile of mucous melanoma lesions with anti-melanoma associated antigen and anti-HLA mAb Melanoma Research. 3: 85. DOI: 10.1097/00008390-199303000-00318 |
0.449 |
|
| 1993 |
Ferrone S. HLA antigen expression by melanoma cells Melanoma Research. 3: 13. DOI: 10.1097/00008390-199303000-00038 |
0.396 |
|
| 1993 |
Wang Z, Albino AP, Houghton A, Ferrone S. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in β2 μmRNA Melanoma Research. 3: 12. DOI: 10.1097/00008390-199303000-00034 |
0.438 |
|
| 1993 |
Mittelman A, Hirai S, Puccio C, Ferrone S. ACTIVE SPECIFIC IMMUNOTHERAPY WITH MOUSE ANTI-IDIOTYPIC MONOCLONAL ANTIBODY MK2-23 IN PATIENTS WITH STAGE IV MELANOMA WITH NO EVIDENCE OF DISEASE. CORRELATION WITH ANTI HIGH MOLECULAR WEIGHT-MELANOMA ASSOCIATED ANTIBODIES Journal of Immunotherapy. 14: 360. DOI: 10.1097/00002371-199311000-00029 |
0.401 |
|
| 1993 |
Gattoni-Celli S, Calorini L, Byers HR, Etoh T, Wang Z, Ferrone S. Abnormalities in HLA Class I Antigen Expression by Melanoma Cells: Structural Characterization and Functional Implications Journal of Investigative Dermatology. 100: S226-S230. DOI: 10.1038/Jid.1993.81 |
0.461 |
|
| 1993 |
Hayashibe K, Tsukamoto H, Kako S, Nagai H, Ichihashi M, Ferrone S. Molecular characterization and tissue distribution of novel. Immunogenic melanoma-associated antigens sythesized in vitro Journal of Dermatological Science. 6: 11. DOI: 10.1016/0923-1811(93)90823-8 |
0.362 |
|
| 1993 |
Iwasaki Y, Cai H, Takabatake H, Shinji T, Grumet F, Ferrone S. A novel type of soluble HLA antigens: anti-idiotypic (anti-id) mAb which bear the internal image of HLA-DQ3 antigens Human Immunology. 37: 125. DOI: 10.1016/0198-8859(93)90161-S |
0.441 |
|
| 1993 |
Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance Trends in Neurosciences. 16: 487-494. |
0.362 |
|
| 1992 |
Moolenaar W, Bruijn JA, Schrama E, Ferrone S, Daha MR, Zwinderman AH, Hoedemaeker PJ, van Es LA, van der Woude FJ. T-cell receptors and ICAM-1 expression in renal allografts during rejection. Transplant International : Official Journal of the European Society For Organ Transplantation. 4: 140-5. PMID 1958278 DOI: 10.1007/Bf00335334 |
0.334 |
|
| 1992 |
Perosa F, Dannecker G, Ferrone S, Dammacco F. Immunochemical and functional characterization of anti-idiotypic antibodies to a mouse anti-CD4 monoclonal antibody. International Journal of Clinical & Laboratory Research. 21: 179-85. PMID 1815763 DOI: 10.1007/Bf02591640 |
0.41 |
|
| 1992 |
Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proceedings of the National Academy of Sciences of the United States of America. 89: 466-70. PMID 1731316 DOI: 10.1073/Pnas.89.2.466 |
0.415 |
|
| 1992 |
Sakaguchi K, Koide N, Takenami T, Matsushima H, Takabatake H, Ferrone S, Tsuji T. Soluble HLA class I antigens in sera of patients with chronic hepatitis. Gastroenterologia Japonica. 27: 206-11. PMID 1577226 DOI: 10.1007/Bf02777724 |
0.406 |
|
| 1992 |
Armandola EA, Mariani SM, Zwickl M, Hardman N, Ferrone S. Molecular analysis of anti-idiotypic monoclonal antibodies in the HLA-DR antigenic system. European Journal of Immunology. 22: 2893-9. PMID 1425914 DOI: 10.1002/Eji.1830221121 |
0.405 |
|
| 1992 |
Tatake RJ, Ferrone S, Zeff RA. The role of beta-2 microglobulin in temperature-sensitive and interferon-γ-induced exocytosis of HLA class I molecules Transplantation. 54: 395-403. PMID 1412716 DOI: 10.1097/00007890-199209000-00002 |
0.448 |
|
| 1992 |
Kageshita T, Yamada M, Arao T, Ferrone S. Expression of high molecular weight-melanoma associated antigen (HMW-MAA) in primary ALM lesions is associated with a poor prognosis. Pigment Cell Research. 132-5. PMID 1409414 DOI: 10.1111/J.1600-0749.1990.Tb00362.X |
0.344 |
|
| 1992 |
Chen ZJ, Yang H, Liu CC, Mittelman A, Ferrone S. Association between induction of anti high molecular weight-melanoma associated antigen (HMW-MAA) immunity with mouse antiidiotypic monoclonal antibody (MoAb) MK2-23 and prolongation of survival in patients with melanoma. Pigment Cell Research. 113-22. PMID 1409413 DOI: 10.1111/j.1600-0749.1990.tb00360.x |
0.323 |
|
| 1992 |
Canton AD, Fuiano G, Sepe V, Caglioti A, Ferrone S. Mesangial expression of intercellular adhesion molecule-1 in primary glomerulosclerosis Kidney International. 41: 951-955. PMID 1381006 DOI: 10.1038/Ki.1992.145 |
0.354 |
|
| 1992 |
Guarini L, Graham GM, Jiang H, Ferrone S, Zucker S, Fisher PB. Modulation of the antigenic phenotype of human melanoma cells by differentiation-inducing and growth-suppressing agents. Pigment Cell Research / Sponsored by the European Society For Pigment Cell Research and the International Pigment Cell Society. 123-31. PMID 1357650 DOI: 10.1111/J.1600-0749.1990.Tb00361.X |
0.487 |
|
| 1992 |
Mariani SM, Armandola EA, Ferrone S. Diversity of anti-HLA-DR antibodies elicited by distinct anti-idiotypic monoclonal antibodies recognizing idiotopes co-expressed by the immunizing monoclonal antibody Immunology. 77: 597-603. PMID 1283602 |
0.342 |
|
| 1992 |
Mariani SM, Armandola EA, Ferrone S. Heterogeneity in the Anti-HLA-DR immune response elicited by the antiidiotype monoclonal antibody F5-444: Analysis at the clonal level Transplantation. 54: 1078-1084. PMID 1281563 DOI: 10.1097/00007890-199212000-00024 |
0.474 |
|
| 1992 |
HAYASHIBE K, ICHIHASHI M, MISHIMA Y, FERRONE S. The identification of strong immunogenic human malignant melanoma antigen. Skin Cancer. 7: 23-25. DOI: 10.5227/skincancer.7.23 |
0.329 |
|
| 1991 |
Wang ZG, Cao Y, D'Urso C, Houghton AN, Ferrone S. Molecular abnormalities in the expression of HLA class-I antigens by melanoma cells. International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement. 6: 101-5. PMID 2066175 DOI: 10.1002/Ijc.2910470720 |
0.516 |
|
| 1991 |
D'Errico A, Facchini A, Meliconi R, Grigioni FW, Ferrone S. Reactivity of monoclonal antibody (mAb) GD9 with a cytoplasmic antigen preserved in formalin-fixed, paraffin-embedded gastrointestinal tumors. Hybridoma. 10: 113-9. PMID 2032731 DOI: 10.1089/Hyb.1991.10.113 |
0.434 |
|
| 1991 |
Mariani SM, Armandola EA, Ferrone S. Diversity in the fine specificity of anti-HLA-DR monoclonal antibodies elicited with syngeneic antiidiotypic monoclonal antibodies Transplantation Proceedings. 23: 455-456. PMID 1990583 |
0.307 |
|
| 1991 |
Guarini L, Temponi M, Bruce JN, Bollon AP, Duigou GJ, Moulton TA, Ferrone S, Fisher PB. Expression and modulation by cytokines of the intercellular adhesion molecule-1 (ICAM-1) in human central nervous system tumor cell cultures. International Journal of Cancer. 46: 1041-7. PMID 1979069 DOI: 10.1002/Ijc.2910460616 |
0.365 |
|
| 1991 |
Temponi M, Fawwaz RA, Kekish U, Wang TS, Ferrone S. Improvement by affinity chromatography on antiidiotypic monoclonal antibodies (MAbs) of immunoreactivity and in vivo targeting of radiolabelled anti-HMW-MAA MAb TP61.5 in nude mice bearing human melanoma lesions. International Journal of Cancer. 49: 624-30. PMID 1917164 DOI: 10.1002/Ijc.2910490426 |
0.419 |
|
| 1991 |
Maio M, Altomonte M, Tatake R, Zeff RA, Ferrone S. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene Journal of Clinical Investigation. 88: 282-289. PMID 1905328 DOI: 10.1172/Jci115289 |
0.481 |
|
| 1991 |
D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. The Journal of Clinical Investigation. 87: 284-92. PMID 1898655 DOI: 10.1172/Jci114984 |
0.474 |
|
| 1991 |
Chen ZJ, Yang H, Ferrone S. Human high molecular weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody MK2-23: Characterization of the immunogenicity in syngeneic hosts Journal of Immunology. 147: 1082-1090. PMID 1861071 |
0.353 |
|
| 1991 |
Ruggiero G, Racioppi L, Manzo C, Pirozzi G, D'Oro U, Ferrone S, Zappacosta S, Fontana S. HLA class II molecules on monocytes regulate T cell proliferation through physical interaction in the CD3 activation pathway. European Journal of Immunology. 21: 29-33. PMID 1825060 DOI: 10.1002/Eji.1830210106 |
0.431 |
|
| 1991 |
Ghose T, Ferrone S, Blair AH, Kralovec Y, Temponi M, Singh M, Mammen M. Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight-melanoma associated antigen. Cancer Immunology, Immunotherapy : Cii. 34: 90-6. PMID 1760821 DOI: 10.1007/Bf01741341 |
0.454 |
|
| 1991 |
Mariani SM, Armandola EA, Ferrone S. Diversity in the fine specificity and idiotypic profile of mouse anti-HLA-DR monoclonal antibody elicited with the syngeneic anti-idiotypic monoclonal antibody F5-830 Journal of Immunology. 147: 1322-1330. PMID 1714480 |
0.327 |
|
| 1991 |
Coli A, Bigotti G, Ferrone S. Histiocytosis X arising in Hodgkin's disease: immunophenotypic characterization with a panel of monoclonal antibodies Virchows Archiv a Pathological Anatomy and Histopathology. 418: 369-373. PMID 1708928 DOI: 10.1007/Bf01600168 |
0.455 |
|
| 1991 |
De Felice M, Giarrusso PC, Lamberti A, Turco MC, Valerio G, van Lier RA, Yang SY, Ferrone S, Venuta S. Mitogenic activity of anti-CD28 MoAb CLB-CD28/1 on peripheral blood mononuclear cells and its cooperation with other anti-T cells MoAb in the activation of purified T lymphocytes. Tissue Antigens. 36: 12-8. PMID 1701062 DOI: 10.1111/J.1399-0039.1990.Tb01792.X |
0.347 |
|
| 1991 |
Graham GM, Guarini L, Moulton TA, Datta S, Ferrone S, Giacomini P, Kerbel RS, Fisher PB. Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons. Cancer Immunology, Immunotherapy : Cii. 32: 382-90. PMID 1672507 DOI: 10.1007/Bf01741333 |
0.44 |
|
| 1991 |
Reddy PG, Graham GM, Datta S, Guarini L, Moulton TA, Jiang HP, Gottesman MM, Ferrone S, Fisher PB. Effect of recombinant fibroblast interferon and recombinant immune interferon on growth and the antigenic phenotype of multidrug-resistant human glioblastoma multiforme cells. Journal of the National Cancer Institute. 83: 1307-15. PMID 1653364 DOI: 10.1093/Jnci/83.18.1307 |
0.378 |
|
| 1991 |
Turco M, Alfinito F, De Felice M, Lamberti A, Ferrone S, Venuta S. T-cell malignancies with mature phenotypes: altered cell cycle regulation by HLA class I molecules Blood. 78: 2045-2052. DOI: 10.1182/Blood.V78.8.2045.Bloodjournal7882045 |
0.445 |
|
| 1991 |
Arkin S, Naprstek B, Guarini L, Ferrone S, Lipton J. Expression of intercellular adhesion molecule-1 (CD54) on hematopoietic progenitors Blood. 77: 948-953. DOI: 10.1182/Blood.V77.5.948.Bloodjournal775948 |
0.381 |
|
| 1991 |
Shimizu B, Sra K, Ferrone S, Pouletty P. sHLA-STATTM class I, an ELISA for quantification of HLA antigens in serum Human Immunology. 32: 94. DOI: 10.1016/0198-8859(91)90290-P |
0.311 |
|
| 1990 |
Perosa F, Kageshita T, Ono R, Ferrone S. Serological methods to detect anti-idiotypic antibodies. Methods in Enzymology. 178: 74-90. PMID 2689842 DOI: 10.1016/0076-6879(89)78007-1 |
0.347 |
|
| 1990 |
O'Connell MJ, Chen ZJ, Yang H, Yamada M, Massaro M, Mittelman A, Ferrone S. Active specific immunotherapy with antiidiotypic antibodies in patients with solid tumors. Seminars in Surgical Oncology. 5: 441-7. PMID 2688034 DOI: 10.1002/Ssu.2980050611 |
0.426 |
|
| 1990 |
Guarini L, Temponi M, Edwalds GM, Vita JR, Fisher PB, Ferrone S. In vitro differentiation and antigenic changes in human melanoma cell lines. Cancer Immunology, Immunotherapy : Cii. 30: 262-8. PMID 2624919 DOI: 10.1007/Bf01744892 |
0.476 |
|
| 1990 |
Temponi M, Pupa S, Ferrone S. Purification of immunoreactive radiolabeled monoclonal antibodies with anti-idiotypic monoclonal antibodies Journal of Immunological Methods. 126: 223-229. PMID 2406347 DOI: 10.1016/0022-1759(90)90154-N |
0.389 |
|
| 1990 |
Flajnik MF, Ferrone S, Cohen N, Pasquier LD. Evolution of the MHC: Antigenicity and unusual tissue distribution of Xenopus (frog) class II molecules Molecular Immunology. 27: 451-462. PMID 2366760 DOI: 10.1016/0161-5890(90)90170-5 |
0.454 |
|
| 1990 |
Shinji T, Ono R, Ferrone S. Fine specificity and idiotype diversity of a murine anti-HLA-DQw3 monoclonal antibody elicited with a syngeneic antiidiotypic monoclonal antibody Journal of Immunology. 144: 4291-4297. PMID 2341722 |
0.335 |
|
| 1990 |
Schenkelaars EJ, Bonta IL, Ferrone S, Quagliata F. Macrophage function during the development of adjuvant disease. Agents and Actions. 29: 111-3. PMID 2327311 DOI: 10.1007/Bf01964735 |
0.373 |
|
| 1990 |
Perosa F, Carbone R, Ferrone S, Dammacco F. Purification of human immunoglobulins by sequential precipitation with caprylic acid and ammonium sulphate. Journal of Immunological Methods. 128: 9-16. PMID 2324507 DOI: 10.1016/0022-1759(90)90458-8 |
0.35 |
|
| 1990 |
De Felice M, Turco MC, Costanzo F, Corbo L, Ferrone S, Venuta S. Inhibition by anti-HLA class I mAb of IL-2 and IL-2 receptor synthesis in lymphocytes stimulated with PHA-P. Cellular Immunology. 126: 420-7. PMID 2311126 DOI: 10.1016/0008-8749(90)90333-M |
0.323 |
|
| 1990 |
Ferrone S. Monoclonal antibodies and tumor vaccines Current Opinion in Oncology. 2: 1146-1151. PMID 2099845 DOI: 10.1097/00001622-199012000-00020 |
0.356 |
|
| 1990 |
Manzo C, Ruggiero G, del Vecchio L, Racioppi L, Pirozzi G, Temponi M, Ferrone S, Fontana S, Zappacosta S. Monoclonal antibody OKT3-induced T cell proliferation: differential role of HLA class II determinants expressed by T cells and monocytes. Cellular Immunology. 125: 79-91. PMID 1688405 DOI: 10.1016/0008-8749(90)90064-X |
0.458 |
|
| 1990 |
Kageshita T, Arao T, Ferrone S. Antiidiotypic monoclonal antibodies to anti human high molecular weight-melanoma associated antigen monoclonal antibodies Journal of Dermatological Science. 1: 116. DOI: 10.1016/0923-1811(90)90246-A |
0.424 |
|
| 1990 |
Yi PN, Alfieri AA, Temponi M, Ferrone S, Moorthy C, Hilaris BS. Binding affinity of antigen-antibody complexes at clinically relevant hyperthermic temperatures: A proposed model International Journal of Radiation Oncology*Biology*Physics. 19: 249-250. DOI: 10.1016/0360-3016(90)90889-R |
0.342 |
|
| 1989 |
Kumari HL, Shuler CF, Lehman T, Ferrone S, Milo GE. Development of neoplastic phenotype following transfection of hnf cells with sarcoma dna Carcinogenesis. 10: 401-404. PMID 2912591 DOI: 10.1093/Carcin/10.2.401 |
0.429 |
|
| 1989 |
Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S. Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma. 8: 85-95. PMID 2784406 DOI: 10.1089/Hyb.1989.8.85 |
0.344 |
|
| 1989 |
Scambia G, Benedetti Panici P, Baiocchi G, Coli A, Ferrone S, Natali PG, Mancuso S. A primary amelanotic melanoma of the vagina diagnosed by immunocytochemistry. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 29: 159-64. PMID 2568292 DOI: 10.1016/0020-7292(89)90847-3 |
0.33 |
|
| 1989 |
Maio M, Gulwani B, Tombesi S, Ferrone S. Modulation by cytokines of HLA antigens, intercellular adhesion molecule 1 and high molecular weight melanoma associated antigen expression and of immune lysis of clones derived from the melanoma cell line MeM 50-10 Cancer Immunology Immunotherapy. 30: 34-42. PMID 2513111 DOI: 10.1007/Bf01665028 |
0.519 |
|
| 1989 |
Maio M, Gulwani B, Morgano A, Ferrone S. Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells International Journal of Cancer. 44: 554-559. PMID 2506138 DOI: 10.1002/Ijc.2910440330 |
0.434 |
|
| 1989 |
Ziai MR, Ferrone S. Specific phosphorylation by calcium-egta complex of a 75kda human tumor plasma membrane protein (pp75) International Journal of Biochemistry. 21: 731-738. PMID 2503405 DOI: 10.1016/0020-711X(89)90203-6 |
0.347 |
|
| Show low-probability matches. |
